documents incorporated reference document part proxy statement annual meeting part iii shareholders held may filed securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets well club stores specialty channels company incorporated new jersey financial information information companys segments see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales sales companys top pharmaceutical products well total sales animal health consumer care products follows millions total sales pharmaceutical januvia zetia remicade gardasil janumet isentress vytorin nasonex proquadmmr iivarivax singulair animal health consumer care revenues revenues primarily comprised alliance revenue miscellaneous corporate revenues thirdparty manufacturing sales october company divested substantial portion thirdparty manufacturing sales table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders certain products within companys franchises follows primary care womens health cardiovascular zetia ezetimibe marketed ezetrol outside united states vytorin ezetimibesimvastatin marketed inegy outside united states cholesterol modifying medicines diabetes obesity januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes respiratory nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms singulair montelukast medicine indicated chronic treatment asthma relief symptoms allergic rhinitis dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma asmanex twisthaler mometasone furoate inhalation powder inhaled corticosteroid firstline maintenance treatment asthma patients years age older womens health endocrine nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring fosamax alendronate sodium treatment prevention osteoporosis follistim aq follitropin beta injection fertility treatment implanon etonogestrel implant singlerod subdermal contraceptive implant cerazette desogestrel progestin oral contraceptive arcoxia etoricoxib treatment arthritis pain company markets outside united states avelox moxifloxacin broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infections company markets united states hospital specialty immunology remicade infliximab simponi golimumab treatment inflammatory diseases company markets europe russia turkey infectious disease isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection cancidas caspofungin acetate antifungal product pegintron peginterferon alphab treatment chronic hepatitis c invanz ertapenem sodium treatment certain infections victrelis boceprevir treatment chronic hepatitis c noxafil posaconazole prevention invasive fungal infections oncology temodar temozolomide marketed temodal outside united states treatment certain types brain tumors emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution company markets outside united states trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic products bridion sugammadex sodium injection medication reversal certain muscle relaxants used surgery integrilin eptifibatide treatment patients acute coronary syndrome diversified brands cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension primaxin imipenem cilastatin sodium antibacterial product zocor simvastatin statin modifying cholesterol propecia finasteride product treatment male pattern hair loss clarinex desloratadine nonsedating antihistamine remeron mirtazapine antidepressant claritin rx loratadine treatment seasonal outdoor allergies yearround indoor allergies proscar finasteride urology product treatment symptomatic benign prostate enlargement maxalt rizatriptan benzoate product acute treatment migraine vaccines gardasil human papillomavirus quadrivalent types vaccine recombinant vaccine help prevent certain diseases caused four types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps table contents rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpes zoster pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorders cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiencies beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products nobivac vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals activylscaliborexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develops manufactures markets overthecounter foot care sun care products principal products segment include overthecounter products claritin nondrowsy antihistamines miralax relief occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn oxytrol women treatment overactive bladder women foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils discussion sales companys products see item managements discussion analysis financial condition results operations joint ventures astrazeneca lp merck entered agreement astra ab astra develop market astra products united states merck astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec omeprazole first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra restructured joint venture whereby merck acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights table contents company earns certain partnership returns well ongoing revenue based sales kbi products partnership returns include priority return provided partnership agreement preferential return representing companys share undistributed partnership azlp generally accepted accounting principles gaap earnings variable return related companys limited partner interest astrazeneca option purchase mercks interest kbi based part value mercks interest nexium prilosec astrazenecas option exercisable march april astrazeneca chooses exercise option closing date expected june amended agreement astrazeneca make payment merck upon closing million reflecting estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june exercise price also include additional amount equal multiple ten times mercks average annual profit allocation partnership three years prior exercise company believes likely astrazeneca exercise option astrazeneca exercises option company longer record equity income azlp supply sales azlp terminate addition company recognize noncash pretax gain approximately million sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution thenexisting european union eu european free trade association merck sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory licenses subsidiary scheringplough corporation scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases schering ploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company exclusive marketing rights products throughout europe russia turkey december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission ec approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi eu following receipt pricing reimbursement approval within eu profits derived mercks exclusive distribution two products countries equally divided merck jj competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer animal health care manufacturers companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect intangible assets table contents associated certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands health care environment global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation began implemented various insurance market reforms advanced continue full implementation law expected expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion billion fee assessed company proportion share sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee full impact us health care reform predicted time company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue table contents generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company efforts toward health care cost containment remain intense several european countries many countries continued announce execute austerity measures include implementation pricing actions reduce prices generic patented drugs mandatory switches generic drugs company taking steps mitigate impact countries austerity measures continued negatively affect companys revenue performance company anticipates austerity measures continue negatively affect revenue performance addition majority countries attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement companys focus share revenue emerging markets increased governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tend focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance us food drug administration fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription table contents pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck announced would launch merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth initiative merck leveraging scientific business expertise help make proven solutions widely available develop new technologies improve public policymaker awareness issues merck also past provided funds merck foundation independent organization partnered variety organizations dedicated improving global health one partnerships african comprehensive hivaids partnership botswana collaboration government botswana renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including recently enacted laws regulations united states europe asia latin america increased enforcement litigation activity united states developed markets distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers companys overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets well club stores specialty channels raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business table contents patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including patent term restoration pediatric exclusivity major marketed products product year expiration us asmanex use formulation dulera useformulation combination integrilin compound useformulation nasonex useformulationformulation emend follistim aq pegintron conjugates mature ifnalpha invanz compound composition zostavax use zetiavytorinliptruzet nuvaring delivery system emend injection noxafil rotateq intron recombivax method makingvectors januviajanumetjanumet xr compound salt zioptan pending patent term restoration isentress victrelis pending patent term restoration gardasil compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities agreement apotex generic manufacturer granted rights mercks nasonex use patent united states addition district court decision upheld appeal court appeals federal circuit found apotexs proposed generic product would infringe mercks nasonex formulation patent thus apotexs application approved fda enter market united states generic version nasonex agreement generic manufacturer may launch generic version zetia united states december expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries table contents agreement apotex inc apotex corp collectively apotex granted rights mercks nasonex use patent united states addition district court decision upheld appeal court appeals federal circuit found apotexs proposed generic product would infringe mercks nasonex formulation patent thus apotexs application approved fda enter market united states generic version nasonex company anticipates sales nasonex united states decline significantly patent expiries generic entry additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review united states fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review year expiration us mk corifollitropin alfa injection formulationuse mk sugammadex sodium injection mk vorapaxar mk timothy grass pollen allergen extract use mk short ragweed pollen allergen extract use v hpv vaccine valent mk suvorexant september merck received complete response letter crl fda resubmission new drug application sugammadex sodium injection mk address crl company conducting hypersensitivity study anticipates filing new drug application resubmission fda june merck received crl fda suvorexant mk february company resubmitted new drug application fda company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us v inactivated varicella zoster virus vzv vaccine use v pediatric hexavalent combination vaccine method makingvectors mk odanacatib mk vintafolide mk anacetrapib mk tildrakizumab composition mka actoxumabbezlotoxumab mk mk omarigliptin mk mk ertugliflozin unless otherwise noted patents charts compound patents patent subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five table contents years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion billion included restructuring costs years well million million million inprocess research development impairment charges respectively company prioritizes research development efforts focus candidates believes represent breakthrough science make difference patients payers increased emphasis externally sourced programs company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities merck moved diversify portfolio collaboration development biosimilars potential harness market opportunity presented biological medicine patent expiries delivering high quality biosimilars enhance access patients worldwide company committed making externally sourced programs greater component pipeline strategy renewed focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company evaluating certain latestage clinical development platform technology assets determine outlicensing sale potential january company entered agreement divest sirna therapeutics inc subsidiary related rnai technology assets companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia neurodegenerative diseases osteoporosis respiratory diseases womens health development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologics molecule believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans table contents favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced review staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds table contents products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples pharmaceutical medical devices agency japan health canada agencia nacional de vigilancia brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review united states internationally mk vorapaxar investigational antithrombotic medicine review fda ema merck seeking approval vorapaxar reduction atherothrombotic events added standard care patients history heart attack history stroke transient ischemic attack january fdas cardiovascular renal drugs advisory committee recommended approval vorapaxar fda bound committees guidance takes advice consideration reviewing investigational medicines v companys ninevalent hpv vaccine development help protect certain hpvrelated diseases review fda v incorporates antigens five additional cancercausing hpv types compared gardasil company anticipates submitting maa ema first half mk corifollitropin alfa injection investigational fertility treatment review fda controlled ovarian stimulation women participating assisted reproductive technology approved corifollitropin alfa would first sustained follicular stimulant use fertility treatment regimen united states mercks corifollitropin alfa currently approved markets outside united states including eu mk grastek timothy grass pollen allergen extract investigational timothy grass pollen allergy immunotherapy tablet ait mk ragwitek short ragweed pollen allergen extract investigational ragweed pollen ait review fda grastek proposed trade name mk ragwitek proposed trade name mk mk mk investigational sublingual tablets designed help treat underlying cause allergic rhinitis generating immune response help protect allergic patients effects triggered targeted allergen merck partnered alkabello develop investigational sublingual allergy immunotherapy tablets timothy grass pollen ragweed pollen house dust mites north america december fdas allergenic products advisory committee positive discussion mk january advisory committee positive discussion mk fda bound committees guidance takes advice consideration reviewing investigational medicines merck expects fdas review mk mk completed first half february company announced grastek received regulatory approval canada mk suvorexant investigational insomnia medicine new class medicines called orexin receptor antagonists use patients difficulty falling staying asleep july company announced received crl fda regarding nda suvorexant crl fda advised merck efficacy suvorexant established doses mg mg elderly nonelderly adult patients mg starting dose patients must available suvorexant approved mg mg doses would appropriate patients mg dose welltolerated effective patients taking concomitant moderate cypa inhibitors mg dose would necessary addition fda determined safety data support approval suvorexant mg mg february company resubmitted nda fda previously disclosed fda approval separate scheduling table contents determination us drug enforcement administration required merck introduce suvorexant united states insomnia condition characterized difficulty falling asleep andor staying asleep company submitted new drug application suvorexant health authorities japan continuing plans seek approval suvorexant countries around world mk sugammadex sodium injection investigational agent reversal neuromuscular blockade induced rocuronium vecuronium neuromuscular blocking agents neuromuscular blockade used anesthesiology induce muscle relaxation surgery september merck announced received crl fda resubmission nda sugammadex sodium injection fdas letter raised concerns operational aspects hypersensitivity study agency requested address crl company conducting hypersensitivity study anticipates filing nda resubmission fda sugammadex sodium injection approved launched many countries outside united states marketed bridion mk vintafolide investigational cancer candidate review ema part exclusive license agreement endocyte inc endocyte merck responsible development worldwide commercialization vintafolide oncology ema accepted maa filings vintafolide endocytes investigational companion diagnostic imaging agent etarfolatide targeted treatment patients folatereceptor positive platinumresistant ovarian cancer combination pegylated liposomal doxorubicin vintafolide etarfolatide granted orphan drug status ec vintafolide phase development united states mk vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis c virus hcv infection review japan addition candidates regulatory review company drug candidates phase development targeting broad range diseases company anticipates filing nda bla applicable fda respect several candidates mk investigational antipd immunotherapy currently evaluated treatment patients advanced melanoma tumor types january company announced started rolling submission fda bla mk patients advanced melanoma previously treated ipilimumab rolling submission allows completed portions application submitted reviewed fda ongoing basis company expects complete application first half april merck announced mk received breakthrough therapy designation advanced melanoma fda noted designation investigational drug breakthrough therapy intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints mk clinical development program also includes studies across broad range cancer types including bladder colorectal gastric head neck melanoma nonsmall cell lung renal triple negative breast hematological malignancies addition company announced four collaborations pharmaceutical companies evaluate novel combination regimens mk mk odanacatib oral onceweekly investigational treatment patients osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis july merck announced update phase trial assessing fracture risk reduction odanacatib independent data monitoring committee dmc study completed first planned interim analysis efficacy recommended study closed early due robust efficacy favorable benefitrisk profile dmc noted safety issues remain certain selected areas made recommendations respect following february merck announced recently received reviewing safety efficacy data phase trial result review data company concluded review additional data previously planned ongoing extension study warranted filing application approval fda table contents delayed previously announced company conducting blinded extension trial approximately women provide additional safety efficacy data merck continues anticipate file applications approval odanacatib additional data extension trial company continues believe odanacatib potential address unmet medical needs patients osteoporosis v investigational hexavalent pediatric combination vaccine contains components current vaccines designed help protect six potentially serious diseases diphtheria tetanus whooping cough bordetella pertussis polio poliovirus types invasive disease caused haemophilus influenzae type b hepatitis b developed collaboration sanofipasteur company continues anticipate filing bla v fda mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc anacetrapib evaluated large eventdriven cardiovascular clinical outcomes trial reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease predicted completed mk mercks novel investigational oral amyloid precursor protein sitecleaving enzyme bace inhibitor treatment alzheimers disease evaluated phase clinical trial epoch designed evaluate safety efficacy mk versus placebo patients mildto moderate alzheimers disease based positive dmc recommendation made following planned analysis interim safety data included safety cohort patients treated mk least three months company recently began enrolling patients phase portion trial well new phase trial apecs designed evaluate safety efficacy mk versus placebo patients amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination two monoclonal antibodies used treat patients single infusion mk omarigliptin investigational onceweekly dipeptidyl peptidase dpp inhibitor development treatment type diabetes mk ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes company entered worldwide except japan collaboration agreement pfizer inc development commercialization ertugliflozin mk insulin glargine candidate treatment patients type type diabetes february company announced expanded collaboration samsung bioepis develop manufacture commercialize mk terms agreement companies collaborate clinical development regulatory filings manufacturing approved merck commercialize candidate v inactivated vzv vaccine development prevention herpes zoster company conducting two phase trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies mk tildrakizumab antiinterleukin monoclonal antibody candidate investigated treatment psoriasis mkmk alloral combination regimen phase development consisting mk investigational hcv nsa protease inhibitor mk investigational hcv nsa replication complex inhibitor granted breakthrough therapy designation october fda treatment chronic hcv infection mk mk investigated broad clinical program includes studies patients multiple hcv genotypes treatmentnave treatment failures well important hcv subpopulations patients cirrhosis coinfected hiv mka nomace marketed zoely eu investigational oral contraceptive use women prevent pregnancy november merck received crl fda nomace merck made decision discontinue phase clinical trial nomace conducted united states decision based new safety efficacy findings table contents may company provided update clinical program preladenant mercks investigational adenosine aa receptor antagonist treatment parkinsons disease initial review data three separate phase trials provide evidence efficacy preladenant compared placebo based results merck taken steps discontinue extension phases studies longer plans pursue regulatory filings preladenant decision discontinue studies based safety finding company recorded impairment charge million related discontinuation clinical development program preladenant chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area additional claims line extensions formulations inline products shown phase phase phase entry date review allergy atherosclerosis allergy mk immunotherapy mk anacetrapib may mk grass pollen us alzheimers disease alzheimers disease mk ragweed us mk mk december fertility asthma clostridium difficile infection mk corifollitropin alfa injection us mk mka actoxumabbezlotoxumab hepatitis c bacterial infection november mk vaniprevir japan mk diabetes mellitus hpvrelated cancers cancer mk omarigliptin september v hpv vaccine valent us mk dalotuzumab mk ertugliflozin november insomnia mk mk february mk suvorexant us cmv prophylaxis transplant patients herpes zoster neuromuscular blockade reversal mk letermovir v inactivated vzv vaccine december mk sugammadex sodium injection contraception medicated ius melanoma us mk mk august platinumresistant ovarian cancer contraception next generation ring osteoporosis mk vintafolide eu mka mk odanacatib september thrombosis mkb pediatric hexavalent combination vaccine mk vorapaxar useu hepatitis c v april footnotes mk platinumresistant ovarian cancer north american rights mk mk vintafolide us april new nonproprietary name mk review hiv psoriasis phase adaptive design mk doravirine mk tildrakizumab december january company announced started rolling nonsmall cell lung cancer submission fda bla mk patients mk advanced melanoma previously treated ipilimumab pneumoconjugate vaccine june merck received crl fda suvorexant v mk february company resubmitted nda rheumatoid arthritis fda mk september merck received crl fda resubmission nda sugammadex sodium injection mk address crl company conducting hypersensitivity study anticipates filing nda resubmission fda employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide table contents employees company represented various collective bargaining groups addition companys joint ventures china brazil included consolidated results merck employees restructuring program october company announced new global restructuring program restructuring program part global initiative sharpen commercial research development focus part new program company expects reduce total workforce approximately positions workforce reductions primarily come elimination positions sales administrative headquarters organizations well research development company also reduce global real estate footprint continue improve efficiency manufacturing supply network company continue hire employees strategic growth areas business necessary merger restructuring program subsequent merck scheringplough merger merger company commenced actions global restructuring program merger restructuring program designed streamline cost structure combined company actions program initiated actions program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities since inception merger restructuring program december merck eliminated approximately positions comprised employee separations well elimination contractors vacant positions approximately position eliminations remain pending program older program december restructuring actions merger restructuring program substantially completed end exception certain actions principally manufacturingrelated subsequent merger company rationalized number manufacturing sites worldwide remaining actions program result additional manufacturing facility rationalizations expected substantially completed environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million million million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion table contents operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck expanded operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business provided item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating table contents companies us patents potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain products loss could result material noncash impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products chart listing us patent protection companys major marketed products set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects patent provides market exclusivity eu nasonex expired january company anticipates sales decline significantly also court ruled proposed generic form nasonex made apotex generic manufacturer infringe companys us patent nasonex apotex receives approval market united states generic form nasonex company experience loss nasonex sales addition september ec approved biosimilar remicade company experiencing generic competition certain smaller european markets company anticipates substantial decline remicade sales following loss market exclusivity major european markets february key company products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products januvia zetia remicade gardasil janumet isentress vytorin nasonex result companys dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postmarket trials increased competition introduction new effective treatments discontinuation removal market product reason events material adverse effect sales certain products event could result material noncash impairment charge companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may table contents take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications increasing uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection mergers acquisitions company devoting substantial resources development mk mercks antipd immunotherapy assurance approved marketing fda january company announced initiated rolling submission fda bla mk company 's antipd immunotherapy patients advanced melanoma previously treated ipilimumab company also stated expected complete submission first half assurance company complete submission fda approve mk marketing sale united states initial indication additional indications addition approved assurance mk succeed marketplace companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities table contents united states including fda foreign regulatory authorities including eu united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postmarketing phase trials studies may decrease demand companys products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lower costgeneric products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection table contents significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead noncash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition products measured fair value capitalized connection mergers acquisitions companys portfolio products marketed treatment chronic hepatitis c vytorin zetia experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products company faces pricing pressure respect products company faces increasing pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition company faces risk litigation government pricing calculations outside united states numerous major markets including eu japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered congress state legislatures major health care reform adopted law important market reforms begun continue full implementation new law expected expand access health care million americans end decade minimum rebate states participating medicaid program increased companys branded prescription drugs medicaid rebate extended medicaid managed care organizations eligibility federal b drug discount program table contents extended rural referral centers sole community hospitals critical access hospitals certain free standing cancer hospitals certain additional childrens hospitals addition law requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also company required pay annual health care reform fee assessed branded prescription drug manufacturers importers fee calculated based industrys total sales branded prescription drugs specified government programs percentage manufacturers sales included determined tiered scale based manufacturers individual revenues manufacturers portion total annual fee based manufacturers proportion total includable sales prior year annual industry fee billion billion company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business uncertainty global economic conditions together austerity measures taken certain governments could negatively affect companys operating results uncertainty global economic conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects global efforts toward health care cost containment continue exert pressure product pricing market access many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan austerity measures continue negatively affect revenue performance company continues monitor credit economic conditions within greece spain italy portugal among members eu economic conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding countries may also impact likelihood collecting outstanding accounts receivable december companys accounts receivable greece italy spain portugal totaled approximately million amount hospital public sector receivables approximately million aggregate approximately related greece italy spain portugal respectively december companys total accounts receivable outstanding one year approximately million approximately related accounts receivable greece italy spain portugal mostly comprised hospital public sector receivables credit economic conditions europe worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations table contents diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease company evaluating strategic options merck consumer care animal health businesses however assurance transactions occur january company announced evaluating respective roles mercks animal health consumer care businesses companys strategy longterm value creation furthermore company stated expects complete evaluation process take action company could reach different decisions two businesses assurance company determine take action respect either business able effectuate action determines take company experienced difficulties delays manufacturing certain products previously disclosed merck past experienced difficulties manufacturing certain vaccines products company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales company faces significant litigation related vioxx september merck voluntarily withdrew vioxx arthritis acute pain medication market worldwide although merck settled major portion us product liability litigation company still faces material litigation arising voluntary withdrawal vioxx addition vioxx product liability lawsuits lawsuits certain states participate previouslydisclosed settlement various purported class actions individual lawsuits brought merck several current former officers directors merck alleging merck made false misleading statements regarding vioxx violation federal securities laws state laws suits referred vioxx securities lawsuits vioxx securities lawsuits transferred judicial panel multidistrict litigation us district court district new jersey district judge stanley r chesler inclusion nationwide multidistrict litigation consolidated purposes merck also named defendant actions various countries outside united states suits referred vioxx international lawsuits vioxx litigation discussed fully item financial statements supplementary data note contingencies environmental liabilities company believes meritorious defenses vioxx product liability lawsuits vioxx securities lawsuits vioxx international lawsuits collectively vioxx litigation vigorously defend companys insurance coverage respect vioxx litigation adequate cover defense costs losses company currently able estimate additional amounts may required pay connection vioxx litigation proceedings still expected continue years company predict course proceedings take view inherent difficulty predicting outcome litigation company unable predict outcome matters time reasonably estimate possible loss range loss respect remaining vioxx litigation company established material reserves potential liability relating remaining vioxx litigation although established reserves related table contents settlement certain vioxx international lawsuits respect certain vioxx product liability lawsuits discussed item financial statements supplementary data note contingencies environmental liabilities unfavorable outcomes vioxx litigation resulting payment substantial damages could material adverse effect companys business cash flow results operations financial position prospects issues concerning vytorin enhance clinical trial adverse effect sales vytorin zetia united states results improveit trial could material adverse effect sales company sells vytorin zetia previously disclosed january company announced results enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease improveit trial currently underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients presenting acute coronary syndrome scheduled completion later incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established improveit trial blinded interim efficacy analyses conducted data safety monitoring board dsmb trial approximately endpoints accrued respectively case dsmb recommended continuing trial without change design dsmb completed another planned interim review study data march recommended study continue issues concerning enhance clinical trial adverse effect sales vytorin zetia could continue adverse effect sales results improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin sales zetia vytorin could materially adversely affected sales products materially adversely affected companys business cash flow results operations financial position prospects could also materially adversely affected company could required record material noncash impairment charge company may able realize expected benefits investments emerging markets company taking steps increase presence emerging markets however guarantee companys efforts expand sales emerging markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected instance february venezuelan government devalued currency result devaluation company recognized losses due exchange venezuelan government devalue currency company would recognize additional losses due exchange company expects impact would greater addition china governmental investigations involving multinational pharmaceutical companies domestic health care companies medical institutes adversely affected companys near term growth prospects market company continues believe china represents important growth table contents opportunity events coupled heightened scrutiny health care industry may continue impact product pricing market access generally company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however failure continue expand companys business emerging markets could material adverse effect business financial condition results companys operations company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows occurred venezuela order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued april president obamas administration reproposed significant changes us international tax laws including changes would tax companies excess returns attributable certain offshore intangible assets limit us tax deductions expenses related unrepatriated foreignsource income modify us foreign tax credit rules potentially significant changes us international laws including move toward territorial tax system taxing currently accumulated unrepatriated foreign earnings controlled foreign corporations set various congressional committees company determine whether proposals enacted law changes may made proposals prior enacted law changes us international tax laws enacted could significant impact financial results company addition company may affected changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business table contents reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure size complexity companys computer systems makes potentially vulnerable service interruption malicious intrusion random attacks addition data privacy security breaches employees others may pose risk data including intellectual property personal information may exposed unauthorized individuals public assurance companys efforts protect data systems prevent service interruption loss critical sensitive information could result financial legal business reputational harm company negative events animal health industry could negative impact future results operations future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant company voluntarily suspended sales zilmax animal feed supplement united states canada concerns raised cattle fed zilmax suspension materially reduced sales zilmax company give assurances sales zilmax united states canada resume biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing table contents procedures required human vaccine candidates fda approval required release manufactured commercial lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living micro organisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability table contents obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant litigation related vioxx fosamax legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters currently located whitehouse station new jersey although company announced intends move headquarters kenilworth new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd whitehouse station companys vaccines business conducted divisional headquarters located west point pennsylvania mercks animal health consumer care global headquarters functions located summit new jersey although company announced vacate summit property principal us research facilities located rahway kenilworth summit new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facilities outside united states located netherlands switzerland china company also production facilities human health products locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia table contents capital expenditures billion billion billion united states amounted million billion billion abroad expenditures amounted million million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable executive officers registrant ages february time merger november certain executive officers assumed position newly merged company noted kenneth c frazier age december chairman president chief executive officer merck co inc january president chief executive officer merck co inc may president merck co inc responsible companys three largest worldwide divisions global human health merck manufacturing division merck research laboratories prior may mr frazier executive vice president president global human health merck co inc adele ambrose age november senior vice president chief communications officer merck co inc responsible global communications organization december vice president chief communications officer merck co inc responsible global communications organization john canan age november senior vice president financeglobal controller merck co inc responsible companys global controllers organization including accounting controls external reporting financial standards policies january senior vice president controller merck co inc responsible corporate controllers group willie deese age november executive vice president president merck manufacturing division merck co inc responsible companys global manufacturing procurement distribution logistics functions january executive vice president president merck manufacturing division merck co inc responsible companys global manufacturing procurement distribution logistics functions table contents richard r deluca jr age september executive vice president president merck animal health merck co inc responsible merck animal health organization prior september mr deluca chief financial officer becton dickinson biosciences medical technology company since president wyeths fort dodge animal health division also served chief operating officer fort dodge executive vice president chief financial officer cuong viet age october executive vice president chief strategy officer merck co inc responsible leading formulation execution companys long term strategic plan prior october mr senior vice president corporate strategy business development te connectivity global company designs manufactures markets products customers variety industries senior vice president chief strategy officer lenovo personal technology company clark golestani age december executive vice president chief information officer merck co inc responsible mercks global information technology august vice president merck research laboratories information technology merck co inc responsible global mercks research development division including basic research preclinical clinical regulatory mirian graddickweir age november executive vice president human resources merck co inc responsible global human resources organization january executive vice president human resources merck co inc responsible global human resources organization bridgette p heller age march executive vice president president merck consumer care merck co inc responsible merck consumer care organization prior march ms heller president johnson johnsons global baby business unit michael j holston age june executive vice president chief ethics compliance officer merck co inc responsible companys compliance function including global safety environment systems assurance ethics privacy prior june mr holston executive vice president general counsel board secretary hewlettpackard company technology company since oversaw legal compliance government affairs privacy ethics operations peter n kellogg age november executive vice president chief financial officer merck co inc responsible companys worldwide financial organization investor relations corporate development global facilities companys joint venture relationships august executive vice president chief financial officer merck co inc responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships table contents bruce n kuhlik age november executive vice president general counsel merck co inc responsible legal communications public policy functions january executive vice president general counsel merck co inc responsible legal communications public policy functions roger perlmutter age april executive vice president president merck research laboratories merck co inc responsible companys research development efforts worldwide prior april dr perlmutter executive vice president research development amgen inc michael rosenblatt md age december executive vice president chief medical officer merck co inc companys primary voice global medical community critical issues patient safety oversight companys global center scientific affairs prior december dr rosenblatt dean tufts university school medicine since adam h schechter age may executive vice president president global human health merck co inc responsible companys pharmaceutical vaccine worldwide business november president global human health us marketintegration leader merck co inc commercial responsibility united states companys portfolio prescription medicines leader integration efforts merckscheringplough merger across divisions functions august president global pharmaceuticals global human health merck co inc global responsibilities companys atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchises well commercial responsibility united states companys portfolio prescription medicines february board accepted resignation john canan retire company march elected rita karachun senior vice president finance global controller effective march making companys principal accounting officer ms karachun age served assistant controller company since november prior appointment assistant controller company ms karachun served assistant controller scheringplough corporation since february responsible preparing financial statements worldwide consolidation international entities officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low january approximately shareholders record issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors may purchase billion merck shares includes million shares received october upon settlement accelerated share repurchase agreement cash paid period table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp performance graph reflects scheringploughs stock performance december close merger mercks stock performance november december assumes cash component merger consideration reinvested merck stock closing price november compound annual growth rate discussed november merck scheringplough completed merger merck subsequently renamed merck sharp dohme corp msd became whollyowned subsidiary scheringplough subsequently renamed merck co inc result merger msd longer exists publicly traded entity ceased trading common stock close business merger date msd permanently removed peer group index addition abbott laboratories abbott currently included peer group however abbott spun pharmaceutical business abbvie inc future company intends remove abbott peer group calculation performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed securities exchange commission subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include amortization purchase accounting adjustments impact restructuring actions intangible asset impairment charges including inprocess research development impairment charges reflected research development expenses favorable impact certain tax items amounts include amortization purchase accounting adjustments net charge recorded connection settlement certain shareholder litigation inprocess research development impairment charges reflected research development expenses impact restructuring actions favorable impact certain tax items amounts include amortization purchase accounting adjustments inprocess research development impairment charges reflected research development expenses impact restructuring actions arbitration settlement charge favorable impact certain tax items including net favorable impact approximately million relating settlement federal income tax audit amounts include amortization purchase accounting adjustments inprocess research development impairment charges billion reflected research development expenses impact restructuring actions reserve related vioxx litigation gain recognized astrazeneca lps exercise option acquire certain assets company favorable impact certain tax items amounts include impact merger scheringplough corporation november including recognition gain representing fair value stepup mercks previously held interest merckscheringplough partnership result obtaining controlling interest amortization purchase accounting adjustments recorded postmerger period also included gain sale mercks interest merial limited favorable impact certain tax items impact restructuring actions amount reflects dividends declared merck common stock addition approximately million dividends paid subsequent merger scheringplough million paid prior merger relating common stock preferred stock dividends declared scheringplough number employees december reflect employees companys joint ventures china brazil included consolidated results merck table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets well club stores specialty channels overview companys revenue performance tempered ongoing business challenges including recent product patent expiries ongoing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide sales billion decline compared including unfavorable effect foreign exchange decline driven primarily recent loss market exclusivity several products particularly singulair medicine indicated chronic treatment asthma relief symptoms allergic rhinitis well maxalt product acute treatment migraine propecia product treatment male pattern hair loss temodar treatment certain types brain tumors company experienced significant rapid decline sales products following loss market exclusivity declines partially offset higher sales vaccines immunology diabetes hiv products company continued successfully execute cost reduction initiatives marketing administrative expenses research development costs billion combined basis compared reflecting targeted reductions promotional spending lower costs result portfolio prioritization effort drive companywide efficiencies merck taking several strategic operating actions response business challenges rapidly changing external environment facing designed drive short longterm growth october company announced multiyear global initiative sharpen commercial research development focus designed enable merck better allocate resources candidates believes capable providing unambiguous promotable advantages patients payers includes bolstering pipeline implementing agile operating model significantly reduced flexible cost structure still maintaining high level cash returned shareholders geographically company increase focus ten prioritized markets account majority revenue pharmaceutical vaccine business markets united states japan france germany canada united kingdom china brazil russia korea company continue invest highgrowth key emerging markets within core human pharmaceutical vaccine business merck continue support inline portfolio prepare promising launches pipeline company increase focus key therapeutic areas meet unmet medical needs provide best opportunities business deliver greatest value customers diabetes acute hospital care vaccines oncology part intensified portfolio assessment process company divested portion us ophthalmics business sold us marketing rights saphris table contents antipsychotic indicated treatment schizophrenia bipolar disorder adults companys portfolio assessment process ongoing future product divestitures may occur addition january company announced evaluating respective roles mercks animal health consumer care businesses companys strategy longterm value creation company expects complete evaluation process take action company could reach different decisions two businesses companys refocused research development efforts include programs companys antipd immunotherapy mk oncology received breakthrough therapy designation us food drug administration fda advanced melanoma mercks bace inhibitor alzheimers disease mk companys oral combination regimen treatment chronic hepatitis c virus infection mkmk v ninevalent human papillomavirus hpv vaccine january company announced initiated rolling submission biologics license application bla fda mk patients advanced melanoma previously treated ipilimumab company received breakthrough therapy designation mkmk advanced combination phase b diverse range chronic hepatitis c patients company initiated phase trials bace inhibitor mk filed bla fda v merck pursuing emerging product opportunities independent therapeutic area modality building biologics capabilities company expects make externally sourced programs greater component pipeline strategy company entered collaboration agreement development commercialization ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes phase clinical development company outlicensing discontinuing selected latestage clinical development assets reducing focus platform technologies company outlicensed mk investigational treatment certain types ovarian cancer january entered agreement divest sirna therapeutics inc subsidiary related rnai technology assets company currently several candidates review fda mk vorapaxar investigational antithrombotic medicine also review european union eu v ninevalent hpv vaccine mk corifollitropin alfa injection investigational fertility treatment mk grastek investigational timothy grass pollen allergy immunotherapy tablet ait mk ragwitek investigational ragweed pollen ait also mk vintafolide investigational cancer candidate review eu mk vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis c virus infection review japan february company resubmitted new drug application nda fda mk suvorexant responding agencys complete response letter crl received addition company anticipates resubmitting nda application fda mk sugammadex sodium injection medication reversal certain muscle relaxants used surgery company received crl see research development company also candidates phase development anticipates filing new drug application nda bla applicable fda respect several candidates including completion rolling submission bla mk patients advanced melanoma previously treated ipilimumab october connection implementation companys new global initiative company announced global restructuring program restructuring program part program company expects reduce total workforce approximately positions workforce reductions primarily come elimination positions sales administrative headquarters organizations well research development company also reduce global real estate footprint continue improve efficiency manufacturing supply network company recorded total pretax costs billion related restructuring program actions restructuring program expected substantially completed end cumulative pretax costs estimated approximately billion billion company expects actions restructuring program result annual net cost savings approximately billion end company anticipates actions restructuring program combined remaining actions merger restructuring program discussed result annual net cost savings billion end compared fullyear expense levels table contents global restructuring program merger restructuring program initiated subsequent merck scheringplough corporation scheringplough merger merger intended streamline cost structure combined company workforce reductions associated plan relate elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company recorded total pretax costs billion million billion related restructuring program restructuring actions merger restructuring program substantially completed end exception certain actions principally manufacturingrelated subsequent merger company rationalized number manufacturing sites worldwide remaining actions program result additional manufacturing facility rationalizations expected substantially completed company expects estimated total cumulative pretax costs program approximately billion billion yield annual savings upon completion program approximately billion billion costs associated companys restructuring actions included materials production costs marketing administrative expenses research development expenses restructuring costs company estimates projected costs associated mentioned restructuring programs approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company returned billion cash shareholders stock buyback activity dividend payments pursuant billion share repurchase program approved may mercks board directors merck entered accelerated share repurchase asr agreement goldman sachs co goldman sachs asr merck repurchased million shares common stock billion utilizing funding underwritten public debt offering also november mercks board directors raised companys quarterly dividend per share per share earnings per common share assuming dilution attributable common shareholders eps compared eps years reflect net unfavorable impact resulting acquisitionrelated costs restructuring costs certain items nongaap eps excludes items compared see nongaap income nongaap eps decline nongaap eps compared due primarily lower sales reflecting loss market exclusivity certain products particularly singulair lower equity income higher foreign exchange losses partially offset lower operating expenses eps benefited lower average shares outstanding due asr program discussed competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer animal health care manufacturers companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system table contents strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands health care environment global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation began implemented various insurance market reforms advanced continue full implementation law expected expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion billion fee assessed company proportion share sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee full impact us health care reform predicted time company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company efforts toward health care cost containment remain intense several european countries many countries continued announce execute austerity measures include implementation pricing actions table contents reduce prices generic patented drugs mandatory switches generic drugs company taking steps mitigate impact countries austerity measures continued negatively affect companys revenue performance company anticipates austerity measures continue negatively affect revenue performance addition majority countries attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement companys focus share revenue emerging markets increased governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tend focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies table contents procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck announced would launch merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth initiative merck leveraging scientific business expertise help make proven solutions widely available develop new technologies improve public policymaker awareness issues merck also past provided funds merck foundation independent organization partnered variety organizations dedicated improving global health one partnerships african comprehensive hivaids partnership botswana collaboration government botswana renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including recently enacted laws regulations united states europe asia latin america increased enforcement litigation activity united states developed markets operating results sales worldwide sales totaled billion decline compared billion sales decline driven primarily lower sales singulair patents provided us market exclusivity market exclusivity number major european markets singulair expired august february respectively company experienced significant rapid decline singulair sales markets thereafter foreign exchange unfavorably affected global sales performance revenue decline also reflects lower sales maxalt cozaar hyzaar treatments hypertension temodar clarinex nonsedating antihistamine pegintron treatment chronic hepatitis c propecia fosamax treatment osteoporosis vytorin cholesterol modifying medicine declines partially offset growth gardasil vaccine help prevent certain diseases caused four types hpv remicade simponi treatments inflammatory diseases janumet treatment type diabetes isentress treatment hiv infection dulera inhalation aerosol combination medicine treatment asthma zostavax vaccine help prevent shingles herpes zoster sales united states billion decline compared billion sales decrease driven primarily lower sales singulair well maxalt temodar victrelis oral medicine treatment chronic hepatitis c virus clarinex partially offset higher sales gardasil zetia cholesterol absorption inhibitor dulera inhalation aerosol international sales billion decline compared billion foreign exchange unfavorably affected international sales performance decline driven primarily lower sales pharmaceutical segment reflecting declines japan largely attributable unfavorable effect foreign exchange europe partially offset growth emerging markets sales japan declined billion due unfavorable effect foreign exchange sales decline table contents reflects ongoing impacts loss market exclusivity several products including cozaar hyzaar well lower sales gardasil reflecting japanese governments decision suspend proactive recommendation hpv vaccines declines pegintron rebetol products treatment chronic hepatitis c declines partially offset volume growth januvia treatment type diabetes nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms zetia rotateq vaccine help protect rotavirus gastroenteritis infants children sales europe declined billion including favorable effect foreign exchange driven ongoing generic erosion fiscal austerity measures region partially offset growth remicade simponi janumet januvia isentress sales emerging markets grew billion including unfavorable effect foreign exchange reflecting higher sales vaccine hospital hepatitis immunology products partially offset lower sales singulair diversified brands total international sales represented total sales respectively global efforts toward health care cost containment continue exert pressure product pricing market access worldwide many international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan austerity measures continue negatively affect revenue performance october company sold active pharmaceutical ingredient api manufacturing business effective december certain related products within diversified brands november merck sold us rights certain ophthalmic products january sold us rights saphris aggregate annual sales associated divested assets approximately million annual sales associated divested products approximately million approximately million related pharmaceutical segment million related consumer care segment annual sales associated divested api manufacturing business approximately million related nonsegment revenues worldwide sales billion decline compared billion foreign exchange unfavorably affected global sales performance sales decrease driven primarily singulair lost market exclusivity united states august resulting significant rapid decline us singulair sales sales decline also driven lower sales remicade largely result arbitration settlement agreement reached discussed addition lower sales cozaar hyzaar clarinex fosamax vytorin primaxin antibacterial product avelox broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infections well lower revenue companys relationship astrazeneca lp azlp also contributed sales decline declines largely offset higher sales januvia gardasil victrelis zostavax janumet isentress zetia dulera inhalation aerosol well higher sales companys animal health consumer care products table contents sales companys products follows primary care womens health cardiovascular zetia vytorin diabetes obesity januvia janumet respiratory nasonex singulair dulera asmanex womens health endocrine nuvaring fosamax follistim aq implanon cerazette arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress cancidas pegintron invanz victrelis noxafil oncology temodar emend cosopttrusopt bridion integrilin diversified brands cozaarhyzaar primaxin zocor propecia clarinex remeron claritin rx proscar maxalt vaccines gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sales segment sales total segment sales amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health consumer care alliances alliances segment includes revenue companys relationship azlp revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results discussed october company divested substantial portion thirdparty manufacturing sales addition revenues reflect million revenue outlicense pipeline compound table contents pharmaceutical segment primary care womens health cardiovascular worldwide sales zetia also marketed ezetrol outside united states cholesterol absorption inhibitor billion increase compared including unfavorable effect foreign exchange sales increase primarily reflects favorable pricing united states volume growth japan partially offset unfavorable effect foreign exchange particularly japan sales zetia increased billion including unfavorable effect foreign exchange sales increase reflects positive performance united states due pricing well volume growth japan partially offset volume declines united states global sales vytorin marketed outside united states inegy combination product containing active ingredients zetia zocor statin modifying cholesterol billion decline compared driven primarily lower volumes united states latin america partially offset volume growth asia pacific region worldwide sales vytorin declined billion including unfavorable effect foreign exchange sales decline reflects volume declines united states partially offset pricing united states volume growth certain international markets march data safety monitoring board dsmb improveit trial large cardiovascular outcomes study evaluating ezetimibesimvastatin simvastatin alone patients presenting acute coronary syndrome completed planned review study data recommended study continue merck remains blinded actual results analysis improveit safety efficacy data improveit patient eventdriven trial based targeted number clinical endpoints rate events reported trial projected conclude later results improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin sales zetia vytorin could materially adversely affected company may take non cash impairment charges respect carrying values zetia vytorin intangible assets billion billion respectively december charges could material diabetes obesity global sales januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabetes billion decline compared including unfavorable effect foreign exchange excluding negative effect foreign exchange sales performance compared reflects volume growth japan positive performance europe emerging markets partially offset declines united states reflecting lowering demand worldwide sales januvia rose billion compared reflecting volume growth united states well international markets particularly japan foreign exchange unfavorably affected sales performance company anticipates dpp inhibitors including januvia subject repricing japan trial evaluating cardiovascular outcomes treatment sitagliptin tecos eventdriven cardiovascular outcomes study sitagliptin began patients enrolled tecos evaluate impact sitagliptin added usual care compared usual care without sitagliptin large highrisk type diabetes population across multiple countries tecos expected completed later worldwide sales janumet mercks oral antihyperglycemic agent combines sitagliptin januvia metformin single tablet billion increase compared driven primarily volume growth outside united states global sales janumet billion increase compared reflecting volume growth united states emerging markets europe foreign exchange unfavorably affected sales performance global sales combined diabetes franchise januviajanumet billion increase compared including unfavorable effect foreign exchange billion increase compared including unfavorable effect foreign exchange table contents respiratory global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms increased billion compared driven primarily increases united states reflecting net favorable adjustments indirect customer discounts well volume growth japan partially offset declines latin america canada europe foreign exchange unfavorably affected global sales performance agreement generic manufacturers able launch generic version nasonex european markets january generic versions nasonex since launched several markets accordingly company anticipates rapid decline nasonex sales europe sales nasonex europe million apotex inc apotex corp collectively apotex filed application fda seeking approval sell generic version nasonex june us district court district new jersey ruled company patent infringement suit apotex holding apotexs generic version nasonex infringe companys formulation patent june court appeals federal circuit issued decision affirming us district court decision company exhausted appeal options apotexs generic version becomes available significant losses us nasonex sales could occur company may take noncash impairment charge respect carrying value nasonex intangible asset billion december nasonex intangible asset determined impaired impairment charge could material us sales nasonex million worldwide sales nasonex declined billion including unfavorable impact foreign exchange sales performance compared reflects price declines europe lower volumes united states largely offset higher prices united states worldwide sales singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis fell billion compared driven primarily lower sales united states europe result generic competition patent provided us market exclusivity singulair expired august company lost nearly sales singulair united states addition patents provided market exclusivity singulair expired number major european markets february company experienced significant rapid reduction sales singulair markets following patent expiries expects decline continue patent provides market exclusivity singulair japan expire singulair sales japan million global sales singulair declined billion compared driven primarily lower sales united states revenue declines europe canada latin america also contributed singulair sales decline global sales dulera inhalation aerosol combination medicine treatment asthma million million million reflecting higher demand united states dulera inhalation aerosol approved fda june january merck received crl fda companys supplemental new drug application dulera inhalation aerosol treatment chronic obstructive pulmonary disease company determined conduct additional clinical study longer pursue update application womens health endocrine worldwide sales nuvaring vaginal contraceptive product million increase compared primarily reflecting volume growth favorable pricing united states global sales nuvaring million comparable sales foreign exchange unfavorably affected sales performance excluding unfavorable impact foreign exchange sales performance reflects volume growth emerging markets positive performance europe worldwide sales fosamax marketed fosamac japan fosamax plus marketed fosavance throughout eu treatment case fosamax prevention osteoporosis declined million decreased million driven declines regions medicines lost market exclusivity united states major international markets company expects sales declines within fosamax product franchise continue global sales follistim aq marketed countries outside united states puregon fertility treatment grew million compared driven largely positive performance united states sales follistim aq declined million including unfavorable effect foreign table contents exchange driven largely declines europe resulting supply issues pricing puregon lost market exclusivity eu august worldwide sales implanon singlerod subdermal contraceptive implant grew million compared driven primarily volume growth united states partially offset declines emerging markets pricing pressures implanon sales increased million including unfavorable effect foreign exchange reflecting volume growth emerging markets united states recent years company experienced difficulties manufacturing certain womens health products company resolved issues material companys results operations products included primary care womens health include among others asmanex twisthaler inhaled corticosteroid asthma cerazette progestin oral contraceptive arcoxia treatment arthritis pain avelox broadspectrum fluroquinolone antibiotic treatment certain respiratory skin infections marketed company united states patent provides us market exclusivity avelox expires march hospital specialty immunology sales remicade treatment inflammatory diseases marketed company europe russia turkey billion increase compared including favorable effect foreign exchange sales growth reflects volume growth europe well russia september ec approved infliximab biosimilar company experiencing generic competition certain smaller european markets company anticipates substantial decline remicade sales following loss market exclusivity major european markets february sales remicade billion decline compared including unfavorable effect foreign exchange prior july remicade marketed company outside united states except japan certain asian markets result agreement reached april amend agreement governing distribution rights remicade simponi effective july merck relinquished marketing rights products certain territories including canada central south america middle east africa asia pacific merck retained exclusive marketing rights throughout europe russia turkey retained territories retained territories remicade sales declined reflects unfavorable effect foreign exchange volume growth europe sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey million million million driven continued launch activities simponi approved european commission ec october september ec approved simponi treatment adult patients moderately severely active ulcerative colitis inadequate response conventional therapy intolerant medical contraindications therapies infectious disease worldwide sales isentress hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection grew billion compared driven primarily volume growth united states europe global sales isentress grew billion compared driven primarily volume growth united states latin america asia pacific region foreign exchange unfavorably affected global sales performance global sales cancidas antifungal product increased million compared reflecting growth emerging markets well europe japan sales cancidas declined million reflects unfavorable effect foreign exchange growth emerging markets worldwide sales pegintron treatment chronic hepatitis c declined million compared reflecting declines regions company believes sales declines attributable part patient treatment delayed health care providers anticipation new therapeutic options becoming available table contents foreign exchange unfavorably affected global sales performance global sales pegintron declined million including unfavorable effect foreign exchange excluding unfavorable impact foreign exchange sales performance reflects volume growth favorable pricing united states volume growth certain emerging markets global sales victrelis oral medicine treatment chronic hepatitis c million decline compared including unfavorable effect foreign exchange sales declines united states europe canada partially offset growth across emerging markets company believes sales declines united states europe canada attributable part patient treatment delayed health care providers anticipation new therapeutic options becoming available sales victrelis million compared million driven postlaunch growth united states internationally particularly europe victrelis approved fda may ec july sales companys products indicated treatment chronic hepatitis c including victrelis pegintron discussed well rebetol continued adversely affected patient treatment delayed health care providers anticipation new therapeutic options becoming available sales rebetol product sold almost entirely international markets particularly adversely affected trend given markets rebetol sold well generic competition worldwide sales rebetol declined million driven declines japan europe cash flow revisions fourth quarter indicated rebetol intangible asset value recoverable undiscounted cash flows basis utilizing market participant assumptions company concluded best estimate fair value intangible asset related rebetol million december resulted impairment charge million recorded within materials production costs event availability new treatment options adversely affects sales products currently marketed company treatment chronic hepatitis c greater extent anticipated company event circumstances arise significantly reduce cash flow projections products company may record additional intangible asset impairment charges future charges could material carrying value intangible assets related products billion aggregate december oncology sales temodar marketed temodal outside united states treatment certain types brain tumors declined million compared foreign exchange unfavorably affected global sales performance sales decline driven primarily generic competition united states europe previously disclosed agreement generic manufacturer launched generic version temodar united states august us patent exclusivity periods otherwise expired february temodar lost patent exclusivity eu accordingly company experiencing sales declines due loss exclusivity markets company expects declines continue sales temodar decreased million including unfavorable effect foreign exchange sales declines europe generic competition offset price increases united states global sales emend prevention chemotherapyinduced postoperative nausea vomiting million increase compared including unfavorable effect foreign exchange largely reflecting volume growth united states emerging markets partially offset decline japan sales emend million increase compared including unfavorable effect foreign exchange reflecting volume growth united states japan worldwide sales ophthalmic products cosopt trusopt million decline compared reflecting unfavorable effect foreign exchange lower sales europe canada due generic competition partially offset volume growth japan patent cosopt expired number major european markets march company experiencing sales declines markets patents provided market exclusivity cosopt trusopt united states trusopt number major european markets previously expired sales cosopt trusopt million decline compared including unfavorable effect foreign exchange sales decline primarily reflects lower sales europe due generic erosion price reductions mitigated part higher cosopt sales japan table contents november merck sold us rights ophthalmic products cosopt cosopt pf azasite akorn inc annual us sales associated ophthalmic products approximately million bridion sugammadex sodium injection reversal certain muscle relaxants used surgery approved launched many countries outside united states sales bridion million increase compared sales growth driven volume growth europe emerging markets japan partially offset unfavorable effect foreign exchange primarily sales japan sales bridion grew million driven primarily higher sales japan emerging markets september company received crl fda resubmission nda sugammadex sodium injection see research development saphris asenapine antipsychotic indicated treatment schizophrenia bipolar disorder adults previously marketed company united states mercks sales saphris million million million asenapine sold brand name sycrest also approved eu treatment bipolar disorder adults commercialization agreement sycrest sublingual tablets mg mg h lundbeck lundbeck makes product supply payments exchange exclusive commercial rights sycrest markets outside united states china japan second quarter company reduced cash flow projections saphrissycrest result reduced expectations international markets united states revisions cash flows indicated saphrissycrest intangible asset value recoverable undiscounted cash flows basis company utilized market participant assumptions considered several different scenarios determine best estimate fair value intangible asset related saphrissycrest compared related carrying value resulted impairment charge million reflected materials production costs january merck sold us rights saphris forest laboratories inc forest terms agreement forest make upfront payments approximately million make additional payments merck based defined sales milestones products contained hospital specialty include among others invanz treatment certain infections noxafil prevention certain invasive fungal infections integrilin treatment patients acute coronary syndrome sold company united states canada diversified brands mercks diversified brands include human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatments hypertension billion decline compared including unfavorable effect foreign exchange decline driven largely lower sales japan europe canada due generic competition unfavorable effect foreign exchange particularly sales japan sales cozaarhyzaar decreased billion driven declines regions patents provided market exclusivity cozaar hyzaar united states number major international markets expired accordingly company experiencing significant declines cozaar hyzaar sales company expects declines continue worldwide sales propecia product treatment male pattern hair loss million decline compared including unfavorable impact foreign exchange decline driven primarily generic competition united states well lower sales japan due largely unfavorable effect foreign exchange company lost us market exclusivity propecia multiple generics entered market accordingly company experiencing significant decline us sales propecia expects decline continue sales propecia declined million compared driven declines europe united states partially offset increases asia pacific region global sales clarinex marketed aerius many countries outside united states nonsedating antihistamine declined million decreased million driven lower volumes united states europe result generic competition company anticipates sales clarinex continue decline table contents global sales maxalt product acute treatment migraine fell million compared driven primarily lower volumes united states due generic competition patent provided us market exclusivity maxalt expired december company experienced significant rapid decline us maxalt sales thereafter addition patents provided market exclusivity maxalt expired number major european markets august company experiencing sales declines markets well sales maxalt million comparable sales reflecting higher sales united states driven favorable pricing offset volume declines europe canada due generic erosion products contained diversified brands include among others primaxin antibacterial product zocor statin modifying cholesterol prescription claritin treatment seasonal outdoor allergies yearround indoor allergies remeron antidepressant proscar urology product treatment symptomatic benign prostate enlargement vaccines following discussion vaccines include sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates see selected joint venture affiliate information supply sales spmsd however included mercks sales gardasil vaccine help prevent certain diseases caused four types hpv grew billion compared driven primarily volume growth united states reflecting continued uptake males females volume growth latin america partially offset lower volumes japan sales included million million respectively purchases us centers disease control prevention cdc pediatric vaccine stockpile june japanese health ministry issued advisory suspend active promotion hpv vaccines accordingly company recorded almost sales gardasil japan second half mercks sales gardasil rose billion compared driven primarily growth united states reflecting continued uptake males higher government purchases cdc pediatric vaccine stockpile well growth emerging markets particularly latin america asia pacific region japan company party certain thirdparty license agreements respect gardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasil sales vary country included materials production costs mercks sales proquad pediatric combination vaccine help protect measles mumps rubella varicella million million million sales proquad affected supply constraints proquad became available united states ordering october mercks sales varivax vaccine help prevent chickenpox varicella million million million mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales varivax mmr ii declined due availability proquad discussed mercks sales zostavax vaccine help prevent shingles herpes zoster adults years age older million million million sales growth compared driven higher demand united states canada well launches within asia pacific region company continuing launch zostavax outside united states sales zostavax affected supply issues mercks sales pneumovax vaccine help prevent pneumococcal disease grew million compared driven primarily volume growth emerging markets well volume price increases united states mercks sales pneumovax increased million due primarily growth united states result price increases higher volumes partially offset declines japan mercks sales rotateq vaccine help protect rotavirus gastroenteritis infants children grew million compared reflecting higher pricing united states volume growth table contents japan mercks sales rotateq declined million reflecting favorable public sector inventory fluctuations partially offset volume growth emerging markets japan segments companys segments animal health consumer care alliances segments material separate reporting january company announced evaluating respective roles mercks animal health consumer care businesses companys strategy longterm value creation company expects complete evaluation process take action company could reach different decisions two businesses animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected competition frequent introduction generic products global sales animal health products billion decline compared including unfavorable effect foreign exchange sales decline reflects lower sales ruminant products primarily zilmax partially offset growth companion animal poultry products august merck animal health voluntarily suspended sales zilmax feed supplement beef cattle united states canada suspension zilmax unfavorably affected animal health sales sales animal health products billion increase compared including unfavorable effect foreign exchange driven positive performance among ruminant poultry companion animal swine products consumer care consumer care products include overthecounter foot care sun care products claritin nondrowsy antihistamines miralax relief occasional constipation dr scholls foot care products coppertone sun care products consumer care product sales affected competition consumer spending patterns global sales consumer care products billion decline compared including unfavorable effect foreign exchange sales decline resulted termination china certain consumer care distribution arrangements reversal sales previously made distributors together associated termination costs excluding items consumer care global sales would increased compared including unfavorable effect foreign exchange reflecting higher sales womens health products partially offset lower sales foot care products company launched oxytrol women first overthecounter treatment overactive bladder women consumer care product sales grew including unfavorable effect foreign exchange billion reflecting higher sales dr scholls coppertone miralax claritin partially offset lower sales marvelon oral contraceptive overthecounter product china discussed december company divested certain products aspen annual sales products reflected within consumer care approximately million alliances alliances segment includes results companys relationship azlp revenue azlp primarily relating sales nexium prilosec million million billion astrazeneca option buy mercks interest subsidiary mercks interest nexium prilosec exercisable company believes likely astrazeneca exercise option see selected joint venture affiliate information astrazeneca exercises option company longer record equity income azlp supply sales azlp terminate addition company recognize noncash pretax gain approximately million table contents costs expenses millions change change materials production marketing administrative research development restructuring costs equity income affiliates income expense net greater includes million million million iprd impairment charges respectively materials production materials production costs billion billion billion costs include expenses amortization intangible assets recorded connection mergers acquisitions totaled billion billion additionally expenses include million amortization purchase accounting adjustments scheringploughs inventories recognized result merger costs include intangible asset impairment charges million million respectively impairment charges related changes cash flow assumptions currently marked products saphrissycrest rebetol see pharmaceutical segment company may recognize additional non cash impairment charges future related product intangibles measured fair value capitalized connection mergers acquisitions charges could material additionally costs include million intangible asset impairment charge related licensing agreement also included materials production costs associated restructuring activities amounted million million million respectively including accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared amortization intangible assets purchase accounting adjustments inventories well restructuring impairment charges noted reduced gross margin percentage points percentage points percentage points excluding impacts gross margin decline compared driven part loss singulair sales result patent expiries united states august major european markets february addition generic competition united states maxalt temodar clarinex propecia coupled changes product mix continued pricing pressures mature markets also negatively affected gross margin gross margin decline compared reflects significant decline singulair sales result loss us market exclusivity partially offset improvements resulting changes product mix company anticipates gross margin continue negatively affected ongoing impacts recent patent expiries additional patent expiries occur marketing administrative marketing administrative expenses declined billion decreased billion largely due lower promotional spending selling costs resulting restructuring activities also reflecting favorable effect foreign exchange expenses include restructuring costs million million million respectively related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed expenses also include million million million acquisitionrelated costs respectively consisting incremental thirdparty integration costs related merger including costs related legal entity system integration acquisitionrelated costs also consist severance costs associated acquisition inspire pharmaceuticals inc part companys formal restructuring programs table contents research development research development expenses billion billion billion research development expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human health related activities approximately billion billion also included research development expenses costs incurred divisions support research development activities including depreciation production general administrative well licensing activity certain costs operating segments including pharmaceutical animal health consumer care segments aggregate billion billion billion respectively decline research development costs compared due targeted reductions lower clinical development spend result portfolio prioritization well lower payments licensing activity research development expenses favorably affected cost savings resulting restructuring activities research development expenses also include inprocess research development iprd impairment charges million million million respectively see research development company may recognize additional noncash impairment charges future cancellation delay pipeline programs measured fair value capitalized connection mergers acquisitions charges could material research development expenses reflect million million million respectively accelerated depreciation asset abandonment costs associated restructuring activities company recorded adjustment accelerated depreciation costs included research development expenses revising previously recorded amounts certain facilities restructuring costs restructuring costs primarily representing separation related costs associated restructuring activities billion million billion respectively costs include million costs related restructuring program nearly remaining costs recorded costs recorded related merger restructuring program separation costs billion million billion respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated approximately positions related restructuring program related merger restructuring program related restructuring program approximately positions related merger restructuring program related restructuring program related legacy scheringplough program approximately positions related merger restructuring program related restructuring program related legacy scheringplough program position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs well contract termination shutdown costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development discussed table contents equity income affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates declined million compared driven primarily lower equity income azlp partially offset higher equity income spmsd equity income affiliates increased million due primarily higher equity income azlp company divested interest johnson johnsonmerck consumer pharmaceuticals company jjmcp joint venture see selected joint venture affiliate information income expense net income expense net million expense compared billion expense reflecting million net charge relating settlement certain shareholder litigation enhance litigation see note consolidated financial statements partially offset higher exchange losses driven million exchange losses related venezuelan currency devaluation see note consolidated financial statements well higher interest expense resulting part issuances debt september may income expense net billion expense compared million expense reflecting million net charge relating settlement enhance litigation gains recognized million disposition companys interest jjmcp joint venture see note consolidated financial statements million sale certain manufacturing facilities related assets see note consolidated financial statements partially offset million charge related resolution arbitration proceeding involving companys rights market remicade simponi higher interest income segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment sales less standard costs certain operating expenses directly incurred segment components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits amortization purchase accounting adjustments acquisitionrelated costs intangible asset impairment charges restructuring costs taxes paid joint venture level portion equity income expenses corporate manufacturing cost centers miscellaneous income expense additionally segment profits reflect charge related settlement enhance litigation recorded arbitration settlement charge gain divestiture companys interest jjmcp joint venture gain sale certain manufacturing facilities related assets recorded unallocated items reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales divested products businesses supply sales pharmaceutical segment profits declined driven primarily effects loss market exclusivity certain products particularly singulair pharmaceutical segment profits increased driven primarily lower operating expenses mostly offset effects loss us market exclusivity singulair table contents taxes income effective income tax rates reflect impacts acquisitionrelated costs restructuring costs partially offset beneficial impact foreign earnings effective tax rate reflects net benefit million settlements certain federal income tax issues net benefits reductions tax reserves upon expiration applicable statutes limitations favorable impact tax legislation enacted first quarter extended rd tax credit well outofperiod net tax benefit approximately million associated resolution previously disclosed legacy scheringplough federal income tax issue see note consolidated financial statements effective tax rate also reflects favorable impacts tax settlement canada revenue agency cra realization foreign tax credits impact favorable ruling state tax matter addition effective tax rate reflects unfavorable impact net charge recorded connection settlement enhance litigation tax benefit recorded reflect impacts rd tax credit expired december result legislation passed extended rd tax credit rd tax credits recognized noted effective tax rate reflects net favorable impact approximately million relating settlement mercks federal income tax audit favorable impact certain foreign state tax rate changes resulted net million reduction deferred tax liabilities intangibles established purchase accounting unfavorable impact million charge related resolution arbitration proceeding involving companys rights market remicade simponi net income earnings per common share net income attributable merck co inc billion billion billion eps declines net income eps compared due primarily lower sales reflecting loss market exclusivity certain products particularly singulair well higher restructuring costs intangible asset impairment charges exchange losses partially offset favorable impact certain tax items lower operating expenses eps benefited lower average shares outstanding due asr program see note consolidated financial statements decreases net income eps compared due primarily net charge recorded connection settlement enhance litigation effects loss us market exclusivity singulair favorable impact tax items partially offset lower marketing administrative expenses lower restructuring costs lower intangible asset impairment charges arbitration settlement charge recorded nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance used management merck providing management believes information enhances investors understanding companys results nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items consist acquisitionrelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance therefore information nongaap income nongaap eps considered addition lieu net income eps prepared accordance generally accepted accounting principles united states gaap additionally since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap income nongaap eps performance company measured basis along performance metrics senior managements annual compensation derived part using nongaap income nongaap eps table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts pretax income reported gaap increase decrease excluded items acquisitionrelated costs restructuring costs items net charge related settlement enhance litigation arbitration settlement charge gain disposition interest jjmcp joint venture gain sale manufacturing facilities related assets taxes income reported gaap estimated tax benefit excluded items net tax benefits settlements federal income tax issues tax benefit foreign state tax rate changes nongaap net income less net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisitionrelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection mergers acquisitions amounts include amortization intangible assets inventory stepup well intangible asset impairment charges also excluded incremental thirdparty integration costs associated merger costs related legal entity system integration well costs associated mergers acquisitions severance costs part companys formal restructuring programs costs excluded management believes costs representative ongoing normal business activities restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment shut related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs company undertaken restructurings different types covered periods therefore charges considered nonrecurring however management excludes amounts nongaap income nongaap eps believes helpful understanding performance continuing business certain items nongaap income nongaap eps exclude certain items items represent substantive unusual items evaluated individual basis evaluation considers quantitative qualitative aspect unusual nature generally represent items either result nature magnitude management would anticipate would occur part companys normal business regular basis table contents certain items comprised net charge recorded connection settlement enhance litigation arbitration settlement charge gain disposition companys interest jjmcp joint venture gain associated sale certain manufacturing facilities related assets also excluded nongaap income nongaap eps tax benefits resolution certain federal income tax issues research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states internationally mk vorapaxar investigational antithrombotic medicine review fda european medicines agency ema merck seeking approval vorapaxar reduction atherothrombotic events added standard care patients history heart attack history stroke transient ischemic attack january fdas cardiovascular renal drugs advisory committee recommended approval vorapaxar fda bound committees guidance takes advice consideration reviewing investigational medicines v companys ninevalent hpv vaccine development help protect certain hpvrelated diseases review fda v incorporates antigens five additional cancercausing hpv types compared gardasil company anticipates submitting marketing authorization application maa ema first half mk corifollitropin alfa injection investigational fertility treatment review fda controlled ovarian stimulation women participating assisted reproductive technology approved corifollitropin alfa would first sustained follicular stimulant use fertility treatment regimen united states mercks corifollitropin alfa currently approved markets outside united states including eu mk grastek investigational timothy grass pollen allergy immunotherapy tablet ait mk ragwitek investigational ragweed pollen ait review fda mk mk investigational sublingual tablets designed help treat underlying cause allergic rhinitis generating immune response help protect allergic patients effects triggered targeted allergen merck partnered alkabello develop investigational sublingual allergy immunotherapy tablets timothy grass pollen ragweed pollen house dust mites north america december fdas allergenic products advisory committee positive discussion mk january advisory committee positive discussion mk fda bound committees guidance takes advice consideration reviewing investigational medicines merck expects fdas review mk mk completed first half february company announced grastek received regulatory approval canada mk suvorexant investigational insomnia medicine new class medicines called orexin receptor antagonists use patients difficulty falling staying asleep july company announced received crl fda regarding nda suvorexant crl fda advised merck efficacy suvorexant established doses mg mg elderly nonelderly adult patients mg starting dose patients must available suvorexant approved mg mg doses would appropriate patients mg dose welltolerated effective patients taking concomitant moderate cypa inhibitors mg dose would necessary addition fda determined safety data support approval suvorexant mg mg february company resubmitted nda fda previously disclosed fda approval separate scheduling determination us drug enforcement administration required merck introduce suvorexant united states insomnia condition characterized difficulty falling asleep andor staying asleep company submitted new drug application suvorexant health authorities japan continuing plans seek approval suvorexant countries around world table contents mk sugammadex sodium injection investigational agent reversal neuromuscular blockade induced rocuronium vecuronium neuromuscular blocking agents neuromuscular blockade used anesthesiology induce muscle relaxation surgery september merck announced received crl fda resubmission nda sugammadex sodium injection fdas letter raised concerns operational aspects hypersensitivity study agency requested address crl company conducting hypersensitivity study anticipates filing nda resubmission fda sugammadex sodium injection approved launched many countries outside united states marketed bridion mk vintafolide investigational cancer candidate review ema part exclusive license agreement endocyte inc endocyte merck responsible development worldwide commercialization vintafolide oncology ema accepted maa filings vintafolide endocytes investigational companion diagnostic imaging agent etarfolatide targeted treatment patients folatereceptor positive platinumresistant ovarian cancer combination pegylated liposomal doxorubicin vintafolide etarfolatide granted orphan drug status ec vintafolide phase development united states mk vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis c virus infection review japan addition candidates regulatory review company drug candidates phase development targeting broad range diseases company anticipates filing nda bla applicable fda respect several candidates mk investigational antipd immunotherapy currently evaluated treatment patients advanced melanoma tumor types january company announced started rolling submission fda bla mk patients advanced melanoma previously treated ipilimumab rolling submission allows completed portions application submitted reviewed fda ongoing basis company expects complete application first half april merck announced mk received breakthrough therapy designation advanced melanoma fda designation investigational drug breakthrough therapy intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints mk clinical development program also includes studies across broad range cancer types including bladder colorectal gastric head neck melanoma nonsmall cell lung renal triple negative breast hematological malignancies addition company announced four collaborations pharmaceutical companies evaluate novel combination regimens mk mk odanacatib oral onceweekly investigational treatment patients osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis july merck announced update phase trial assessing fracture risk reduction odanacatib independent data monitoring committee dmc study completed first planned interim analysis efficacy recommended study closed early due robust efficacy favorable benefitrisk profile dmc noted safety issues remain certain selected areas made recommendations respect following february merck announced recently received reviewing safety efficacy data phase trial result review data company concluded review additional data previously planned ongoing extension study warranted filing application approval fda delayed previously announced company conducting blinded extension trial approximately women provide additional safety efficacy data merck continues anticipate file applications approval odanacatib additional data extension trial company continues believe odanacatib potential address unmet medical needs patients osteoporosis table contents v investigational hexavalent pediatric combination vaccine contains components current vaccines designed help protect six potentially serious diseases diphtheria tetanus whooping cough bordetella pertussis polio poliovirus types invasive disease caused haemophilus influenzae type b hepatitis b developed collaboration sanofipasteur company continues anticipate filing bla v fda mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc anacetrapib evaluated large eventdriven cardiovascular clinical outcomes trial reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease predicted completed mk mercks novel investigational oral amyloid precursor protein sitecleaving enzyme bace inhibitor treatment alzheimers disease evaluated phase clinical trial epoch designed evaluate safety efficacy mk versus placebo patients mildto moderate alzheimers disease based positive dmc recommendation made following planned analysis interim safety data included safety cohort patients treated mk least three months company recently began enrolling patients phase portion trial well new phase trial apecs designed evaluate safety efficacy mk versus placebo patients amnestic mild cognitive impairment due alzheimers disease also known prodromal alzheimers disease mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination two monoclonal antibodies used treat patients single infusion mk omarigliptin investigational onceweekly dpp inhibitor development treatment type diabetes mk ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes company entered worldwide except japan collaboration agreement pfizer inc pfizer development commercialization ertugliflozin discussed mk insulin glargine candidate treatment patients type type diabetes february company announced expanded collaboration samsung bioepis develop manufacture commercialize mk terms agreement companies collaborate clinical development regulatory filings manufacturing approved merck commercialize candidate v inactivated varicella zoster virus vaccine development prevention herpes zoster company conducting two phase trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies mk tildrakizumab antiinterleukin monoclonal antibody candidate investigated treatment psoriasis mkmk alloral combination regimen phase development consisting mk investigational hepatitis c virus nsa protease inhibitor mk investigational hepatitis c virus nsa replication complex inhibitor granted breakthrough therapy designation october fda treatment chronic hepatitis c virus infection mk mk investigated broad clinical program includes studies patients multiple hepatitis c virus genotypes treatmentnave treatment failures well important hepatitis c virus subpopulations patients cirrhosis coinfected hiv mka nomace marketed zoely eu investigational oral contraceptive use women prevent pregnancy november merck received crl fda nomace merck made decision discontinue phase clinical trial nomace conducted united states decision based new safety efficacy findings may company provided update clinical program preladenant mercks investigational adenosine aa receptor antagonist treatment parkinsons disease initial review data table contents three separate phase trials provide evidence efficacy preladenant compared placebo based results merck taken steps discontinue extension phases studies longer plans pursue regulatory filings preladenant decision discontinue studies based safety finding company recorded impairment charge million related discontinuation clinical development program preladenant company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities merck moved diversify portfolio collaboration development biosimilars potential harness market opportunity presented biological medicine patent expiries delivering high quality biosimilars enhance access patients worldwide company committed making externally sourced programs greater component pipeline strategy renewed focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company evaluating certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia neurodegenerative diseases osteoporosis respiratory diseases womens health inprocess research development connection mergers acquisitions company recorded fair value incomplete research projects time acquisition yet reached technological feasibility december balance iprd billion significant projects latestage development include vorapaxar companys bace inhibitor sugammadex sodium injection ait programs discussed approximately million million million respectively iprd projects received marketing approval major market company began amortizing assets based estimated useful lives iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date company may also recover research development expenditures made since acquisition develop program circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded million iprd impairment charges within research development expenses amount million related writeoff intangible asset associated preladenant result discontinuation clinical development program compound addition company recorded impairment charges resulting changes cash flow assumptions certain compounds well pipeline programs previously deprioritized subsequently deemed alternative use period company recorded million iprd impairment charges primarily pipeline programs previously deprioritized subsequently deemed alternative use period company recorded million iprd impairment charges primarily table contents pipeline programs abandoned determined alternative use well expected delays launch timing changes cash flow assumptions certain compounds addition impairment charges related pipeline programs previously deprioritized either deemed alternative use period outlicensed third party consideration less related assets carrying value additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects acquired connection mergers acquisitions phase development human health analogous stage development animal health approximately billion acquisitions divestitures research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth company completed transactions across broad range therapeutic categories merck actively monitoring landscape growth opportunities meet companys strategic criteria april merck pfizer announced entered worldwide except japan collaboration agreement development commercialization pfizers ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes company initiated phase clinical trials ertugliflozin pfizer terms agreement merck pfizer collaborate clinical development commercialization ertugliflozin ertugliflozincontaining fixeddose combinations metformin januvia sitagliptin tablets merck continue retain rights existing portfolio sitagliptincontaining products end merck recorded research development expenses million upfront milestone payments made pfizer pfizer eligible additional payments associated achievement prespecified future clinical regulatory commercial milestones companies share potential revenues certain costs merck pfizer party certain manufacturing supply obligations company pfizer right terminate agreement due material uncured breach insolvency party event safety issue pfizer right terminate agreement upon months notice time following first anniversary first commercial sale collaboration product must assign rights ertugliflozin merck upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization ertugliflozin certain payment obligations september merck astrazeneca announced worldwide outlicensing agreement mercks oral small molecule inhibitor wee kinase mk mk currently evaluated phase clinical studies combination standardofcare therapies treatment patients certain types ovarian cancer terms agreement astrazeneca paid merck million upfront fee company recorded revenue addition merck eligible receive future payments tied development regulatory milestones plus salesrelated payments tiered royalties astrazeneca responsible future clinical development manufacturing marketing january company entered agreement divest sirna therapeutics inc subsidiary related rnai technology assets alnylam pharmaceuticals inc alnylam terms agreement consideration paid alnylam merck consist million cash shares alnylam common stock valued approximately million time agreement addition merck eligible receive million developmental sales milestone payments well singledigit royalties associated certain preclinical candidates transaction subject customary closing conditions expected close first quarter table contents selected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years merck formed number joint ventures astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue million million billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement preferential return representing mercks share undistributed azlp gaap earnings variable return related companys limited partner interest returns aggregated million million million respectively astrazeneca option purchase mercks interest kbi based part value mercks interest nexium prilosec astrazenecas option exercisable march april astrazeneca chooses exercise option closing date expected june amended agreement astrazeneca make payment merck upon closing million reflecting estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june exercise price also include additional amount equal multiple ten times mercks average annual profit allocation partnership three years prior exercise company believes likely astrazeneca exercise option astrazeneca exercises option company longer record equity income azlp supply sales azlp terminate addition company recognize noncash pretax gain approximately million sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe table contents sales joint venture products follows millions gardasil influenza vaccines viral vaccines zostavax rotateq hepatitis vaccines vaccines johnson johnsonmerck consumer pharmaceuticals company merck sold interest jjmcp joint venture jj venture merck jj formed develop manufacture market distribute certain overthecounter consumer products united states canada merck received onetime payment million recognized pretax gain million reflected income expense net partnership assets also included manufacturing facility sales products marketed joint venture million period january september divestiture date capital expenditures capital expenditures billion billion billion expenditures united states million billion billion depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion cash provided operating activities includes payment made company million connection previously disclosed settlement enhance litigation see note consolidated financial statements cash provided operating activities reflects higher contributions defined benefit plans compared cash provided operating activities also includes payment million related resolution certain litigation related vioxx cash provided operating activities includes million payment made jj result arbitration settlement well net payments approximately million internal revenue service result conclusion examination certain mercks federal income tax returns cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders global economic conditions ongoing sovereign debt issues among factors adversely affected foreign receivables certain european countries see note consolidated financial statements company received significant collections successful completing factoring arrangements portion receivables additionally company continues expand emerging markets payment terms tend longer conditions eu emerging markets resulted increase table contents average length time takes collect accounts receivable outstanding thereby adversely affecting cash provided operating activities cash used investing activities billion compared billion primarily reflecting higher proceeds sales securities investments lower capital expenditures partially offset higher purchases securities investments cash used investing activities billion compared billion primarily reflecting higher purchases securities investments partially offset higher proceeds sales securities investments cash used financing activities billion compared billion higher use cash financing activities driven primarily higher purchases treasury stock largely asr agreement discussed well higher payments debt decrease short term borrowings partially offset higher proceeds issuance debt cash used financing activities billion compared billion lower use cash financing activities primarily driven proceeds issuance debt lower payments debt higher proceeds exercise stock options partially offset increased purchases treasury stock decrease shortterm borrowings higher dividends paid stockholders december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments generally cash investments held foreign subsidiaries would subject significant tax payments cash investments repatriated form dividends company records us deferred tax liabilities certain unremitted earnings amounts earned overseas expected indefinitely reinvested outside united states accrual us taxes provided amount cash investments held us foreign subsidiaries fluctuates due variety factors including timing receipt payments normal course business cash provided operating activities united states continues companys primary source funds finance domestic operating needs capital expenditures portion treasury stock purchases dividends paid shareholders companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits operating leases includes future bulk supply purchases company committed connection certain divestitures including disposition api manufacturing business discussed december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments also excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million million respectively pension plans postretirement benefit plans table contents company billion fiveyear credit facility maturing may facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility may company completed underwritten public offering billion senior unsecured notes consisting billion aggregate principal amount notes due million aggregate principal amount floating rate notes due billion aggregate principal amount notes due billion aggregate principal amount floating rate notes due billion aggregate principal amount notes due billion aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option varying redemption prices substantial portion net proceeds notes used repurchase companys common stock pursuant accelerated share repurchase agreement may discussed december company filed securities registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date companys longterm credit ratings assigned moodys investors service standard poors stable outlook aa stable outlook respectively ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november board directors declared quarterly dividend per share companys common stock payable january may company announced board directors authorized additional purchases billion mercks common stock treasury company expects repurchase approximately billion common stock within months following date announcement financed combination debt issuance operating cash flows remainder repurchased time time limit purchases may made open market transactions block transactions exchange privately negotiated transactions company purchased billion common stock million shares treasury includes shares asr agreement discussed company approximately billion remaining may share repurchase program company purchased billion billion common stock respectively previously authorized share repurchase programs may merck entered asr agreement goldman sachs asr merck agreed purchase billion mercks common stock total initial delivery approximately million shares mercks common stock based current market price made goldman sachs merck payment billion made merck goldman sachs may upon settlement asr october merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program bringing total shares received merck program million asr entered pursuant share repurchase program announced may table contents financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premium writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar would yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows table contents primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income taxes would declined approximately million company net long position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange december company net short position relative major foreign currencies consideration forward contracts therefore uniform weakening us dollar would reduced income taxes approximately million measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows february venezuelan government devalued currency bolvar fuertes vef per us dollar vef per us dollar company recognized losses due exchange approximately million resulting remeasurement local monetary assets liabilities new rate since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations march venezuelan government announced creation new foreign exchange mechanism called complimentary system foreign currency acquirement known sicad operates similar auction system allows entities specific sectors bid us dollars used specified import transactions december regulation created sicad auction mechanism amended require central bank venezuela include website weekly average exchange rate implied transactions settled via sicad auction mechanism week december bsf per us dollar company used sicad auction mechanism settle transactions sicad mechanism described auction several attributes inconsistent free market auction accordingly company believe appropriate use sicad rate remeasurement us gaap company continue monitor sicad auction mechanism possible circumstances may change sicad mechanism takes attributes true free market auction sicad rate utilized remeasurement purposes occurs devaluation official rate occurs could result material charge companys future results operations company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income oci remains accumulated comprehensive income aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment table contents foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk company entered payfloating receivedfixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes four swaps maturing notional amounts million effectively convert companys fixedrate notes due floatingrate instruments four swaps maturing notional amounts million effectively convert companys fixedrate notes due floatingrate instruments four swaps maturing one notional amount million two notional amounts million one notional amount million effectively convert companys fixed rate notes due floatingrate instruments three swaps maturing two notional amounts million one notional amount million effectively convert portion companys notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows interest rate swaps outstanding december company terminated payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively converted certain fixedrate notes floatingrate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate result swap terminations company received million cash included million accrued interest corresponding million basis adjustment debt associated terminated interest rate swap contracts deferred amortized reduction interest expense respective term notes cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets well subsequent fair value measurement additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent table contents estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded fair values intangible assets including acquired iprd determined utilizing information available near merger acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset begin amortization judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues table contents recorded net time value money discounts customers collection accounts receivable expected excess one year provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns table contents inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation table contents environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension postretirement benefit plans totaled million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forward looking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return range compared range us pension postretirement benefit plans company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines table contents actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized market related value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed reduce cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses purchased assigned reporting units company tests goodwill impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macro economic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price additionally company evaluates extent fair value exceeded carrying value reporting unit last date valuation performed company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles excluding iprd recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent table contents carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthan temporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income table contents taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forward looking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive income loss net taxes net unrealized gain loss derivatives net reclassifications net unrealized loss gain investments net reclassifications benefit plan net gain loss prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts excludes accounts receivable classified assets see note inventories excludes inventories classified assets see note deferred income taxes current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net tax cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased supera joint venture formation net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges gain disposition interest equity method investment equity income affiliates dividends distributions equity affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments proceeds sale interest equity method investment acquisitions businesses net cash acquired dispositions businesses net cash divested cash inflows outflows net investment hedges net cash used investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets well club stores specialty channels summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded table contents foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using first firstout fifo method inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair values companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci declines fair value equity securities considered thantemporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion table contents advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multiyear implementation enterprisewide resource planning system million million december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses purchased goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed based upon companys recent annual impairment test completed october company concluded goodwill impaired acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows inprocess research development inprocess research development iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed fair value less carrying amount impairment loss recognized operating results research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life amounts due collaborative partners related development activities generally reflected reduction research development expenses specific milestone achieved nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges periods table contents sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards first quarter company adopted guidance issued financial accounting standards board fasb simplifies entity tests indefinitelived intangibles impairment amended guidance allows companies first assess qualitative factors determine whether morelikelythannot indefinitelived intangible asset impaired basis determining whether necessary perform quantitative impairment test adoption guidance impact companys financial position results operations table contents restructuring restructuring program october company announced new global restructuring program restructuring program part global initiative sharpen commercial research development focus part new program company expects reduce total workforce approximately positions workforce reductions primarily come elimination positions sales administrative headquarters organizations well research development company also reduce global real estate footprint continue improve efficiency manufacturing supply network company continue hire employees strategic growth areas business necessary company recorded total pretax costs billion related restructuring program actions restructuring program expected substantially completed end cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs result cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested merger restructuring program subsequent merck scheringplough corporation scheringplough merger merger company commenced actions global restructuring program merger restructuring program designed streamline cost structure combined company actions program initiated actions program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities october company sold active pharmaceutical ingredient api manufacturing business including related manufacturing facility netherlands aspen holdings aspen part planned manufacturing facility rationalizations merger restructuring program conjunction sale parties entered strategic longterm supply agreement whereby aspen supply api company approximately employees support api business transferred merck aspen also connection sale aspen acquired certain branded products merck transferred aspen effective december consideration transaction included cash million notes receivable present value million time disposition notes receivable consist million note present value million due million note present value million payable five years beginning december cash portion consideration company received million fourth quarter remaining million received company january therefore december amount recorded receivable within deferred income taxes current assets consolidated balance sheet conjunction transaction company transferred inventory million property plant equipment million cash million aspen reduced goodwill million intangible assets million assets million recorded million transactionrelated liabilities transaction resulted loss million recorded within restructuring costs table contents company recorded total pretax costs billion million billion related restructuring program since inception merger restructuring program december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions approximately position eliminations remain pending program december include remaining actions restructuring program reported part merger restructuring program discussed restructuring actions merger restructuring program substantially completed end exception certain actions principally manufacturingrelated subsequent merger company rationalized number manufacturing sites worldwide remaining actions program result additional manufacturing facility rationalizations expected substantially completed company expects estimated total cumulative pretax costs program approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested restructuring program october merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness pretax costs million million million recorded respectively related restructuring program since inception restructuring program june merck recorded total pretax accumulated costs billion eliminated approximately positions comprised employee separations elimination contractors vacant positions restructuring program substantially completed exception certain manufacturingrelated actions expected completed july remaining accrued liability future separations restructuring program transferred merger restructuring program remaining activities restructuring program accounted part merger restructuring program segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated year ended december costs depreciation total restructuring program materials production marketing administrative research development restructuring costs merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production marketing administrative restructuring costs year ended december merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production marketing administrative restructuring costs year ended december merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions eliminated restructuring program positions eliminated merger restructuring program approximately positions eliminated restructuring program approximately position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date table contents site closed divested depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather record impairment charge anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note share based compensation activity also reflects net pretax losses gains resulting sales facilities related assets million primarily reflecting loss transaction aspen discussed million million adjustments recorded amounts material period following table summarizes charges spending relating restructuring activities program separation accelerated costs depreciation total restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december merger restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december cash outlays associated restructuring program expected substantially completed end cash outlays associated merger restructuring program substantially completed end exception certain actions principally manufacturingrelated expected substantially completed legacy scheringplough program prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity company recorded million accelerated depreciation costs included materials production costs program substantially complete end table contents acquisitions divestitures research collaborations license agreements company continues strategy establishing external alliances complement substantial internal research capabilities including research collaborations licensing preclinical clinical compounds technology platforms drive near longterm growth company supplements internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds arrangements often include upfront payments royalty profit share payments contingent upon occurrence certain future events linked success asset development well expense reimbursements payments third party september merck astrazeneca announced worldwide outlicensing agreement mercks oral small molecule inhibitor wee kinase mk mk currently evaluated phase clinical studies combination standardofcare therapies treatment patients certain types ovarian cancer terms agreement astrazeneca paid merck million upfront fee company recorded revenue addition merck eligible receive future payments tied development regulatory milestones plus salesrelated payments tiered royalties astrazeneca responsible future clinical development manufacturing marketing april merck pfizer inc pfizer announced entered worldwide except japan collaboration agreement development commercialization pfizers ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluated treatment type diabetes company initiated phase clinical trials ertugliflozin pfizer terms agreement merck pfizer collaborate clinical development commercialization ertugliflozin ertugliflozincontaining fixeddose combinations metformin januvia sitagliptin tablets merck continue retain rights existing portfolio sitagliptincontaining products end merck recorded research development expenses million upfront milestone payments made pfizer pfizer eligible additional payments associated achievement prespecified future clinical regulatory commercial milestones companies share potential revenues certain costs merck pfizer party certain manufacturing supply obligations company pfizer right terminate agreement due material uncured breach insolvency party event safety issue pfizer right terminate agreement upon months notice time following first anniversary first commercial sale collaboration product must assign rights ertugliflozin merck upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization ertugliflozin certain payment obligations february merck supera farma laboratorios sa supera brazilian pharmaceutical company coowned cristlia eurofarma established previously announced joint venture markets distributes sells portfolio pharmaceutical branded generic products merck cristlia eurofarma brazil merck owns joint venture cristlia eurofarma collectively transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values resulted merck recognizing intangible assets currently marketed products million iprd million goodwill million deferred tax liabilities million company also recorded increases noncontrolling interests paidin capital amounts million million respectively transaction closed february accordingly results operations acquired business included companys results operations beginning date fourth quarter result changes cash flows assumptions certain compounds company recorded million impairment charges related iprd recorded supera transaction october merck aicuris entered exclusive licensing agreement provides merck worldwide rights develop commercialize candidates aicuris novel portfolio investigational medicines targeting human cytomegalovirus hcmv including letermovir mk oral latestage antiviral candidate investigated treatment prevention hcmv infection transplant recipients aicuris received upfront payment million approximately million company recorded research development expense eligible milestone payments million based successful achievement development regulatory commercialization goals hcmv candidates including letermovir additional table contents backup candidate well phase candidates designed act via alternate mechanism addition aicuris entitled receive royalty payments reflecting advanced stage clinical program potential products result agreement merck responsible development activities costs agreement may terminated either party event material uncured breach insolvency agreement may terminated merck time event compounds licensed aicuris develop adverse safety profile material adverse issue arises related development efficacy dosing regimen compounds andor event certain patents invalid andor unenforceable certain jurisdictions merck may terminate agreement respect certain compounds successful completion first proof concept clinical trial ii must terminate agreement respect certain compounds merck fails minimally invest compounds addition merck may terminate agreement whole time upon six months prior written notice time completion first phase clinical trial compound aicuris may terminate agreement event merck challenges aicuris patent covering compounds licensed aicuris upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization compounds case termination cause merck certain royalty obligations april company entered agreement endocyte inc endocyte develop commercialize endocytes novel investigational therapeutic candidate vintafolide mk vintafolide currently evaluated phase clinical trial folatereceptor positive platinumresistant ovarian cancer proceed phase trial nonsmall cell lung cancer agreement merck gained worldwide rights develop commercialize vintafolide endocyte received million upfront payment company recorded research development expense eligible milestone payments million based successful achievement development regulatory commercialization goals vintafolide total six cancer indications addition vintafolide receives regulatory approval merck endocyte share equally profits losses united states endocyte receive royalty sales product rest world endocyte retained right copromote vintafolide merck united states merck exclusive right promote vintafolide rest world endocyte responsible majority funding completion proceed trial merck responsible development activities development costs decision rights vintafolide merck right terminate agreement days notice merck endocyte right terminate agreement due material breach insolvency party endocyte right terminate agreement event merck challenges endocyte patent right relating vintafolide upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization vintafolide case termination cause merck certain royalty obligations us profit loss sharing may merck completed acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focused developing commercializing ophthalmic products terms merger agreement merck acquired outstanding shares common stock inspire price per share cash total approximately million transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated inspires product product right intangible assets related deferred tax liabilities deferred tax asset relating inspires net operating loss carryforwards goodwill november merck sold us rights certain ophthalmic products akorn inc including azasite acquired inspire transaction march company sold merck biomanufacturing network provider contract manufacturing development services biopharmaceutical industry wholly owned merck fujifilm corporation fujifilm terms agreement fujifilm purchased equity interests two merck subsidiaries together owned assets merck biomanufacturing network comprising facilities located research triangle park north carolina billingham united kingdom part agreement fujifilm merck committed purchase certain development manufacturing services fair value fujifilm threeyear period following closing transaction transaction resulted gain million reflected income expense net table contents remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company exclusive marketing rights products throughout europe russia turkey december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi european union eu following receipt pricing reimbursement approval within eu profits derived mercks exclusive distribution two products equally divided merck jj april connection agreement merck jj amend agreement governing distribution rights remicade simponi jj received onetime payment merck million company recorded charge income expense net financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows table contents connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premium writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year table contents company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci included cumulative translation adjustment pretax losses million million pretax gains million eurodenominated notes interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk company entered payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes four swaps maturing notional amounts million effectively convert companys fixedrate notes due floatingrate instruments four swaps maturing notional amounts million effectively convert companys fixedrate notes due floatingrate instruments four swaps maturing one notional amount million two notional amounts million one notional amount million effectively convert companys fixed rate notes due floatingrate instruments three swaps maturing two notional amounts million one notional amount million effectively convert portion companys notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows interest rate swaps outstanding december company terminated payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively converted certain fixedrate notes floatingrate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate result swap terminations company received million cash included million accrued interest corresponding million basis adjustment debt associated terminated interest rate swap contracts deferred amortized reduction interest expense respective term notes cash flows contracts reported operating activities consolidated statement cash flows table contents presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts non current assets interest rate swap contracts non current noncurrent liabilities foreign exchange contracts current deferred income taxes current assets foreign exchange contracts non current assets foreign exchange contracts current accrued current liabilities derivatives designated hedging instruments foreign exchange contracts current deferred income taxes current assets foreign exchange contracts non current assets foreign exchange contracts current accrued current liabilities table contents noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amount subject offset master netting arrangements offset consolidated balance sheet cash collateral received posted net amounts table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated foreign currency cash flow hedging relationship iii designated foreign currency net investment hedging relationship iv designated hedging relationship years ended december derivatives designated fair value hedging relationship interest rate swap contracts amount loss gain recognized income expense net derivatives amount gain loss recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount loss reclassified aoci sales amount gain loss recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount gain loss recognized oci derivatives derivatives designated hedging relationship foreign exchange contracts amount loss gain recognized income expense net derivatives amount loss recognized sales million ineffectiveness hedge ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information availableforsale investments december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds assetbacked securities us government agency securities commercial paper mortgagebacked securities foreign government bonds equity securities availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds assetbacked securities us government agency securities commercial paper mortgagebacked securities foreign government bonds equity securities assets securities held employee compensation derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities derivative liabilities forward exchange contracts written currency options interest rate swaps total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant transfers level level december cash cash equivalents billion included billion cash equivalents considered level fair value hierarchy company liabilities related contingent consideration considered level fair value hierarchy associated business combinations fair values million million december respectively fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy table contents concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines approximately onethird companys cash cash equivalents invested five highly rated money market funds majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor economic conditions including volatility associated international sovereign economies associated impacts financial markets business taking consideration global economic conditions ongoing sovereign debt issues certain european countries company continues monitor credit economic conditions within greece italy spain portugal among members eu economic conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding time value money discounts recorded customers collection accounts receivable expected excess one year december assets included million million respectively accounts receivable expected collected within one year company expect writeoffs adjustments accounts receivable would material adverse effect financial position liquidity results operations december companys accounts receivable greece italy spain portugal totaled approximately million amount hospital public sector receivables approximately million aggregate approximately related greece italy spain portugal respectively december companys total accounts receivable outstanding one year approximately million approximately related accounts receivable greece italy spain portugal mostly comprised hospital public sector receivables company completed nonrecourse factorings approximately million hospital public sector receivables spain company collected approximately million accounts receivable connection spanish governments debt stabilizationstimulus plan addition company completed nonrecourse factorings approximately million hospital public sector accounts receivable italy additionally company continues expand emerging markets payment terms markets tend longer resulting increase accounts receivable balances certain markets companys customers largest accounts receivable balances amerisourcebergen corporation cardinal health inc mckesson corporation zuellig pharma ltd asia pacific alliance healthcare represented aggregate approximately onefourth total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december company received cash collateral million million respectively various counterparties obligation return collateral recorded accrued current liabilities company advanced cash collateral counterparties december table contents inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost increase lifo costs recognized inventories assets inventories valued lifo method comprised approximately billion billion inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical total goodwill balance january goodwill balance december acquisitions divestitures goodwill balance december includes cumulative translation adjustments goodwill balances certain adjustments additions pharmaceutical segment goodwill resulted formation supera joint venture see note reductions resulted divestiture companys api manufacturing business related branded products see note july company acquired remaining shares physicians interactive provider online mobile clinical resources solutions health care professionals merck existing ownership interest million november merck acquired health management resources corporation leader medical weight management million transactions collectively resulted addition approximately million goodwill included segments pro forma financial information included transactions historical financial results significant compared companys financial results table contents intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights inprocess research development tradenames acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives companys significant acquired intangibles related marketed products december include zetia billion vytorin billion nasonex billion claritin billion nuvaring million well billion aggregate related several products marketed treatment chronic hepatitis c victrelis pegintron rebetol company recorded impairment charges related marketed products million million respectively within material production costs amount recorded million resulted lower cash flow projections saphrissycrest due reduced expectations international markets united states revisions cash flows indicated saphrissycrest intangible asset value recoverable undiscounted cash flows basis company utilized market participant assumptions considered several different scenarios determine best estimate fair value intangible asset related saphrissycrest compared related carrying value resulted impairment charge noted remaining million impairment charges resulted lower cash flow projections rebetol due reduced expectations japan europe revisions cash flows indicated rebetol intangible asset value recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related rebetol compared related carrying value resulted impairment charge noted iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life assets begin amortization million million million respectively iprd reclassified products product rights upon receipt marketing approval major market company recorded million iprd impairment charges within research development expenses amount million related writeoff intangible asset associated preladenant result discontinuation clinical development program compound addition company recorded impairment charges resulting changes cash flow assumptions certain compounds well pipeline programs previously deprioritized subsequently deemed alternative use period company recorded million iprd impairment charges primarily pipeline programs previously deprioritized subsequently deemed alternative use period company recorded million iprd impairment charges primarily pipeline programs abandoned determined alternative use well expected delays launch timing changes cash flow assumptions certain compounds addition impairment charges related pipeline programs previously deprioritized either deemed alternative use period licensed third party consideration less related assets carrying value table contents iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within materials production costs billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following years ended december astrazeneca lp primarily reflects results sanofi pasteur msd johnson johnsonmerck consumer pharmaceuticals company disposed september astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue million million billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement preferential return representing mercks share undistributed azlp gaap earnings variable return related companys limited partner interest astrazeneca option purchase mercks interest kbi based part value mercks interest nexium prilosec astrazenecas option exercisable march april astrazeneca chooses exercise option closing date expected june amended agreement astrazeneca make payment merck upon closing million reflecting estimate fair value mercks interest nexium prilosec portion exercise price subject trueup based actual sales closing june exercise price also include additional amount equal table contents multiple ten times mercks average annual profit allocation partnership three years prior exercise company believes likely astrazeneca exercise option summarized financial information azlp follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities mercks partnership returns azlp generally contractually determined noted based percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion billion billion johnson johnsonmerck consumer pharmaceuticals company merck sold interest johnson johnsonmerck consumer pharmaceuticals company jjmcp joint venture jj venture merck jj formed develop manufacture market distribute certain overthecounter consumer products united states canada merck received onetime payment million recognized pretax gain million reflected income expense net partnership assets also included manufacturing facility sales products marketed joint venture million period january september divestiture date investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets amounts due joint ventures included deferred income taxes current assets million december million december summarized information affiliates excluding azlp disclosed separately follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities noncurrent liabilities includes information jjmcp joint venture divestiture september table contents loans payable longterm debt commitments loans payable december included billion notes due billion commercial paper million shortterm foreign borrowings million longdated notes subject repayment option holder loans payable december included billion notes due billion commercial paper million shortterm foreign borrowings million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings december respectively longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due floatingrate borrowing due notes due notes due notes due notes due notes due floatingrate borrowing due debentures due notes due debentures due notes due debentures due eurodenominated notes due presented table included million million december respectively borrowings variable rates averaging also included foreign borrowings million million december respectively varying rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices may company completed underwritten public offering billion senior unsecured notes consisting billion aggregate principal amount notes due million aggregate principal amount floating rate notes due billion aggregate principal amount notes due billion aggregate principal amount floating rate notes due billion aggregate principal amount notes due billion aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option varying redemption prices substantial portion net proceeds notes used repurchase companys common stock pursuant accelerated share repurchase agreement may see note table contents effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply financial covenants including requirement total debt capitalization ratio defined applicable agreements exceed december company compliance covenants aggregate maturities longterm debt next five years follows billion billion billion billion billion may company entered billion fiveyear credit facility maturing may facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions environmental matters except vioxx litigation defined separate assessment provided note opinion company unlikely resolution matters material companys financial position results operations cash flows given nature litigation discussed including vioxx litigation complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august vioxx litigation product liability lawsuits previously disclosed merck defendant approximately federal state lawsuits vioxx product liability lawsuits alleging personal injury economic loss result purchase use vioxx remaining cases coordinated multidistrict litigation us district court eastern district louisiana vioxx mdl judge eldon e fallon merck reached resolution approved judge fallon remaining federal court putative class actions brought behalf individual purchasers users vioxx seeking reimbursement alleged economic loss settlement merck pay million pay properly documented claims submitted table contents class members approved attorneys fees expenses approved settlement notice costs certain administrative expenses court entered order approving settlement january period members submit claims settlement still pending merck also settled missouri state court class action plaintiffs sought reimbursement outofpocket costs relating vioxx company established reserve million connection settlement agreement minimum amount company required pay agreement settlement approved final judgment action entered courtapproved process class members submit claims settlement closed october indiana plaintiffs filed motion certify class indiana vioxx purchasers case pending circuit court marion county indiana case dormant several years april kentucky state court denied mercks motion summary judgment certified class kentucky plaintiffs seeking reimbursement outofpocket costs relating vioxx trial court subsequently entered amended class certification order january matter settled namedplaintiffonly basis december merck also defendant lawsuits brought state attorneys general four states alaska mississippi montana utah actions pending vioxx mdl proceeding actions allege merck misrepresented safety vioxx suits seek recovery expenditures vioxx governmentfunded health care programs medicaid andor penalties alleged consumer fraud act violations november circuit court franklin county kentucky approved settlement action filed kentucky attorney general merck agreed pay kentucky million resolve lawsuit related appeals shareholder lawsuits previously disclosed addition vioxx product liability lawsuits various putative class actions individual lawsuits federal securities laws state laws filed merck various current former officers directors vioxx securities lawsuits vioxx securities lawsuits coordinated multidistrict litigation us district court district new jersey judge stanley r chesler consolidated purposes august judge chesler granted part denied part mercks motion dismiss fifth amended class action complaint consolidated securities action among things claims based statements made voluntary withdrawal vioxx september dismissed october defendants answered fifth amended class action complaint april plaintiffs filed motion class certification january judge chesler granted motion march plaintiffs filed motion leave amend complaint add certain allegations expand class period may court denied plaintiffs motion leave amend complaint expand class period granted plaintiffs leave amend complaint add certain allegations within existing class period june plaintiffs filed sixth amended class action complaint july defendants answered sixth amended class action complaint discovery completed closed courts scheduling order dispositive motions filed january previously disclosed several individual securities lawsuits filed foreign institutional investors also consolidated vioxx securities lawsuits october plaintiffs filed amended complaints pending individual securities lawsuits also october new individual securities lawsuit kbc lawsuit filed district new jersey several foreign institutional investors case also consolidated vioxx securities lawsuits january defendants filed motions dismiss one individual lawsuits abp lawsuit briefing motions dismiss completed march august judge chesler granted part denied part motions dismiss abp lawsuit among things certain alleged misstatements omissions dismissed inactionable state law claims dismissed full september defendants answered complaints individual actions kbc lawsuit day defendants moved dismiss complaint kbc lawsuit statute limitations grounds december judge chesler denied motion dismiss kbc lawsuit january defendants answered complaint kbc lawsuit discovery completed closed courts scheduling order dispositive motions filed january table contents insurance company directors officers insurance coverage applicable vioxx securities lawsuits remaining stated upper limits approximately million currently used partially fund companys legal fees result previously disclosed insurance arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits international lawsuits previously disclosed addition lawsuits discussed merck named defendant litigation relating vioxx brazil canada europe israel collectively vioxx international lawsuits previously disclosed company entered agreement resolve claims related vioxx canada pursuant company pay minimum approximately million aggregate maximum approximately million agreement approved courts canadas provinces reserves company believes meritorious defenses remaining vioxx product liability lawsuits vioxx securities lawsuits vioxx international lawsuits collectively vioxx litigation vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect remaining vioxx litigation company established reserve respect canadian settlement certain vioxx product liability lawsuits immaterial settlements related certain vioxx international lawsuits company also immaterial remaining reserve relating previously disclosed vioxx investigation nonparticipating states litigation continuing company established liability reserves respect vioxx litigation unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending merck either federal state court including one case seeks class action certification well damages andor medical monitoring approximately actions plaintiffs allege among things suffered osteonecrosis jaw onj generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately actions generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax december merck reached agreement principle plaintiffs steering committee fosamax onj mdl defined resolve pending onj cases appeal fosamax onj mdl state courts aggregate amount million company recorded liability fourth quarter plaintiffs counsel advised company intend participate settlement plan condition settlement state federal onj plaintiffs must also agree participate settlement plan march participation achieved merck may determine whether terminate agreement waive participation requirement agree lesser funding amount settlement fund tentative settlement effect cases alleging femur fractures discussed cases alleging onj andor jaw related injuries august judicial panel multidistrict litigation jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation table contents fosamax onj mdl coordinated pretrial proceedings fosamax onj mdl transferred judge john keenan us district court southern district new york result jpml order approximately cases judge keenan first fosamax onj mdl trial boles v merck fosamax onj mdl court declared mistrial eight person jury could reach unanimous verdict boles case retried june resulted verdict favor plaintiff amount million merck filed posttrial motions seeking judgment matter law alternative new trial october court denied mercks posttrial motions sua sponte ordered remittitur reducing verdict million plaintiff rejected remittitur ordered court requested new trial damages plaintiff merck subsequently entered confidential stipulation amount plaintiffs damages enabled merck appeal underlying judgment merck filed appeal boles case october prior three cases tried verdict fosamax onj mdl defense verdicts favor merck returned three cases plaintiffs filed appeal two cases graves v merck secrest v merck january us court appeals second circuit affirmed judgment mercks favor secrest plaintiff secrest case subsequently filed petition writ certiorari us supreme court denied june february judge keenan ordered two bellwether trials conducted fosamax onj mdl spano v merck jellema v merck selected court tried case dismissed plaintiffs march court selected scheinberg v merck next case tried trial scheinberg case began january february jury returned mixed verdict finding favor merck plaintiffs design defect claim finding favor plaintiff failure warn claim awarded thousand compensatory damages mercks posttrial motion judgment matter law scheinberg case denied july company filed appeal us court appeals second circuit november judge keenan issued order requiring plaintiffs allege certain types specific injuries provide expert reports support claims deadlines submission reports staggered throughout first half date claims approximately plaintiffs subject order dismissed prejudice august judge keenan denied mercks request extend order additional groups plaintiffs also decided start winding fosamax onj mdl remandtransfer remaining cases back proper venues rate cases per month beginning november date subsequently changed plaintiffs request december later suspended indefinitely addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including onj solely seeking medical monitoring designated mass tort centralized management purposes judge carol e higbee atlantic county superior court december approximately onj cases pending merck atlantic county new jersey july judge higbee entered case management order various amendments thereto setting forth schedule contemplates completing fact expert discovery initial group cases reviewed trial february jury rosenberg v merck first trial new jersey coordinated proceeding returned verdict mercks favor april jury sessner v merck second case tried new jersey also returned verdict mercks favor plaintiffs filed appeal cases march new jersey appellate division affirmed judgment mercks favor rosenberg case cases alleging femur fractures march merck submitted motion transfer jpml seeking federal cases alleging femur fractures consolidated one multidistrict litigation coordinated pretrial proceedings motion transfer granted may federal cases involving allegations femur fracture transferred multidistrict litigation district new jersey fosamax femur fracture mdl result jpml order approximately cases pending fosamax femur fracture mdl december case management order entered requiring parties review cases later reduced cases judge joel pisano selected four cases group tried initial bellwether cases fosamax femur fracture mdl first bellwether case glynn v merck began april jury returned verdict mercks table contents favor april addition june judge pisano granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law judge pisano set may trial date bellwether trial case alleged injury took place january following completion fact discovery court selected sweet v merck next fosamax femur fracture mdl case tried may plaintiffs subsequently dismissed case result may trial date withdrawn court expected set october trial date next bellwether trial fosamax femur fracture mdl addition judge pisano entered order august requiring plaintiffs fosamax femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case plaintiffs filed responses show cause order end september merck filed reply responses end october hearing show cause order held january final ruling court pending december approximately cases alleging femur fractures filed new jersey state court pending judge higbee atlantic county superior court parties selected initial group cases reviewed fact discovery first trial new jersey state femur fracture cases su v merck began early march mistrial declared later march plaintiff suffered serious medical issue unrelated use fosamax prevented proceeding trial next trial unanski v merck set tried beginning november continued set trial potentially along one two cases love v merck caravello v merck beginning march additional group cases reviewed fact discovery selected november december approximately cases alleging femur fractures filed california state court petition filed seeking coordinate femur fracture cases filed california state court single judge orange county california petition granted judge steven perk presiding coordinated proceedings november court ordered fact discovery commence parties expected select first round cases included bellwether discovery pool may additionally seven femur fracture cases pending state courts discovery ongoing fosamax femur fracture mdl state courts femur fracture cases pending company intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december approximately cases served pending merck alleging generally use januvia andor janumet caused development pancreatic cancer complaints filed several different state federal courts claims pending consolidated multidistrict litigation proceeding us district court southern district california called incretinbased therapies products liability litigation proceeding includes federal lawsuits alleging pancreatic cancer due use following medicines januvia janumet byetta victoza latter two products manufactured pharmaceutical companies addition cases noted company agreed december toll statute limitations two additional claims company intends defend lawsuits nuvaring previously disclosed beginning may number complaints filed various jurisdictions asserting claims companys subsidiaries organon usa inc organon pharmaceuticals usa inc organon international collectively organon company arising organons marketing sale nuvaring nuvaring litigation combined hormonal contraceptive vaginal ring plaintiffs contend organon schering plough among things failed adequately design manufacture nuvaring failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation nuvaring mdl venued missouri coordinated proceeding new jersey state court table contents december approximately filed nuvaring cases approximately unfiled claims identified response census orders issued nuvaring mdl new jersey proceedings filed cases approximately pending nuvaring mdl us district court eastern district missouri judge rodney sippel approximately pending coordinated proceedings bergen county superior court new jersey judge brian r martinotti proceedings nuvaring mdl new jersey stayed may seven additional cases pending various state courts including cases coordinated state proceeding san francisco superior court california judge john e munter certain state court cases scheduled trial merck negotiating plaintiffs counsel agreed settlement nuvaring litigation intended resolve least cases filed february unfiled claims retainer counsel prior date merck agreed lump total settlement million provided participation settlement least plaintiffs eligible claimants overall certain categories company certain insurance coverage available currently used partially fund companys legal fees insurance coverage also used fund settlement accordingly december companys consolidated balance sheet includes current liability settlement amount corresponding current asset reflecting anticipated insurance recoveries propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar december approximately lawsuits involving total approximately plaintiffs instances spouses joined plaintiffs suits allege experienced persistent sexual side effects following cessation treatment propecia andor proscar filed merck approximately plaintiffs also allege propecia proscar caused cause prostate cancer male breast cancer lawsuits filed various federal courts state court new jersey federal lawsuits consolidated pretrial purposes federal multidistrict litigation judge john gleeson eastern district new york matters pending state court new jersey consolidated judge jessica mayer middlesex county addition one matter pending federal court massachusetts one matter pending state court st louis missouri company intends defend lawsuits vytorinzetia litigation previously disclosed april merck shareholder filed putative class action lawsuit federal court consolidated district new jersey caption merck co inc vytorinzetia securities litigation complaint alleged merck defendants delayed releasing unfavorable results enhance clinical trial regarding efficacy vytorin merck made false misleading statements expected earnings knowing results enhance study released sales vytorin would decline mercks earnings would suffer february merck announced agreement principle plaintiffs settle matter million settlement agreement executed parties june approved court october settlement reflected companys financial results discussed similar consolidated securities class action lawsuit pending district new jersey scheringplough defendants caption scheringplough corporationenhance securities litigation february merck announced agreement principle plaintiffs settle matter million settlement agreement executed june approved court october settlement reflected companys financial results together settlement described preceding paragraph collectively enhance litigation resulted aggregate charge million taking account anticipated insurance recoveries million second quarter company paid million settlement fund companys insurers subsequently paid remaining million reflects additional million insurance recoveries previously recognized november two complaints filed district new jersey merck successor scheringplough defendants certain institutional investors optedout enhance securities class action scheringplough addition january two complaints filed district new jersey merck defendants certain institutional investors optedout vytorinzetia table contents securities class action merck optout complaints contain allegations similar made plaintiffs settled class actions schering plough merck company intends move dismiss complaints otherwise defend litigation governmental proceedings previously disclosed merck received civil investigative demand cid issued us department justice doj addressed inspire company acquired merck may cid advises relates false claims act investigation concerning allegations inspire caused submission false claims federal health benefits programs drug azasite marketing treatment indications approved us food drug administration fda company cooperating doj investigation previously disclosed company received subpoena us attorneys office eastern district california requesting information civil federal health care investigation relating companys marketing selling activities respect integrilin avelox january june december us district court eastern district california unsealed complaint former employee company filed federal false claims act false claims acts various states complaint alleges company caused false claims made federal state health care programs promoting integrilin unapproved indications providing unlawful payments benefits physicians others increase utilization integrilin avelox federal government states whose statutes suit filed right investigating allegations intervene suit assume responsibility direction notified court decline intervene company intends defend lawsuit previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition putative class action lawsuit filed company eastern district pennsylvania behalf direct purchasers mmr ii vaccine predicated allegations false claims act complaint charges company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws company intends defend lawsuits company received subpoena office inspector general us department health human services behalf us attorneys office district maryland civil division doj requests information relating companys marketing singulair dulera certain marketing activities january present company cooperating government previously disclosed company received letters doj sec seek information activities number countries reference foreign corrupt practices act company cooperated agencies requests believes inquiry part broader review pharmaceutical industry practices foreign countries company advised doj based information received closed inquiry matter relates company future company may receive additional requests information either doj sec companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate table contents commercial litigation awp litigation previously disclosed company andor certain subsidiaries named defendants cases brought various states alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used public private payors calculating provider reimbursement levels outcome lawsuits could include substantial damages imposition substantial fines penalties injunctive administrative remedies since start company settled awp cases brought states alabama alaska kansas illinois kentucky louisiana oklahoma mississippi wisconsin subsidiary company continues defendant case brought one state utah company also reinstated defendant putative class action new jersey superior court alleges behalf thirdparty payers individuals manufacturers inflated drug prices manipulation awps means case originally dismissed company without prejudice company intends defend lawsuit kdur antitrust litigation previously disclosed june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications andas following commencement administrative proceeding us federal trade commission ftc alleging anticompetitive effects settlements resolved schering ploughs favor putative class nonclass action suits filed behalf direct indirect purchasers kdur scheringplough upshersmith lederle consolidated multidistrict litigation us district court district new jersey suits claimed violations federal state antitrust laws well state statutory common law causes action sought unspecified damages april indirect purchasers voluntarily dismissed case march district court granted summary judgment defendants remaining lawsuits dismissed matter entirety july third circuit court appeals reversed district courts grant summary judgment remanded case proceedings time third circuit upheld december decision district court certify certain direct purchaser plaintiffs claims class action august company filed petition certiorari us supreme court seeking review third circuits decision june supreme court granted petition vacated judgment third circuit remanded case consideration light recent decision ftc v actavis inc decision held whether socalled reverse payment ie payment holder pharmaceutical patent party challenging patent made connection settlement dispute violates antitrust laws determined basis rule reason analysis september third circuit returned case district court proceedings accordance actavis standard coupon litigation previously disclosed number private health plans filed separate putative class action lawsuits company alleging mercks coupon programs injured health insurers reducing beneficiary copayment amounts thereby allegedly causing beneficiaries purchase higherpriced drugs otherwise would purchased increasing insurers reimbursement costs actions assigned district judge us district court district new jersey sought damages injunctive relief barring company issuing coupons would reduce beneficiary copays behalf putative nationwide classes health insurers similar actions relating manufacturer coupon programs filed several pharmaceutical manufacturers variety federal courts april district court dismissed actions merck without prejudice grounds plaintiffs failed demonstrate standing sue plaintiffs subsequently filed consolidated amended complaint merck filed motion dismiss complaint table contents sales force litigation may ms kelli smith filed complaint company united states district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws november company filed motion dismiss class claims plaintiffs sought granted leave file amended complaint january plaintiffs filed amended complaint adding four additional named plaintiffs company intends refile motion dismiss class allegations otherwise defend patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company products marketed via agreements companies currently involved patent infringement litigation united states include emend injection integrilin nexium nuvaring similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired mergers acquisitions potentially significant intangible asset impairment charges emend injection may patent infringement lawsuit filed united states sandoz inc sandoz respect sandozs application fda seeking prepatent expiry approval market generic version emend injection lawsuit automatically stays fda approval sandozs application july adverse court decision whichever may occur earlier june patent infringement lawsuit filed united states accord healthcare inc us accord healthcare inc intas pharmaceuticals ltd collectively intas respect intas application fda seeking prepatent expiry approval market generic version emend injection company agreed intas stay lawsuit pending outcome lawsuit sandoz integrilin february patent infringement lawsuit filed jointly millennium pharmaceuticals inc united states teva parenteral medicines inc tpm respect tpms application fda seeking prepatent expiry approval sell generic version integrilin october parties entered settlement agreement allowing tpm sell generic version integrilin beginning june november patent infringement lawsuit filed app pharmaceuticals inc fresenius kabi usa inc collectively app respect apps application fda seeking prepatent expiry approval sell generic version integrilin march parties entered settlement agreement allowing app sell generic version integrilin beginning june september patent infringement lawsuit filed ben venue laboratories dba bedford laboratories bedford respect bedfords application fda seeking prepatent expiry approval sell generic version integrilin lawsuit automatically stays fda approval bedfords application february adverse court decision whichever may occur earlier nexium patent infringement lawsuits brought jointly astrazeneca united states following generic companies ranbaxy laboratories ltd ivax pharmaceuticals inc later acquired teva pharmaceuticals inc dr reddys laboratories sandoz lupin ltd hetero drugs limited unit iii torrent pharmaceuticals ltd response generic companys application seeking prepatent expiry approval sell generic version nexium settlements reached lawsuits terms provide respective generic company may bring generic version esomeprazole product market may addition patent infringement lawsuit also filed jointly astrazeneca february united states sun pharma global fze sun pharma respect application fda seeking prepatent expiry approval sell generic version nexium iv lawsuit settled agreement provided sun pharma entitled bring generic esomeprazole iv product market united states january patent infringement lawsuit also filed jointly astrazeneca united states hanmi usa inc hanmi related application fda seeking prepatent expiry approval sell different salt esomeprazole table contents found nexium hanmi product may agreement hanmi conceded validity enforceability patents lawsuit parties also agreed hanmi product would infringe patents district courts december claim interpretation order astrazeneca kbi appealed december court appeals federal circuit denied appeal affirmed district courts claim interpretation order hanmi launched esomeprazole product risk company continues believe courts order incorrect considering options review finally additional patent infringement lawsuits filed jointly astrazeneca united states mylan laboratories limited mylan labs actavis incwatson pharma company collectively actaviswatson related applications fda seeking prepatent expiry approval sell generic versions nexium mylan labs actaviswatson applications fda remain stayed august october respectively earlier adverse court decisions whichever may occur earlier nuvaring december company filed lawsuit warner chilcott company llc warner chilcott united states respect warner chilcotts application fda seeking prepatent expiry approval sell generic version nuvaring patent oppositions ono pharmaceutical co ono european patent broadly claims use antipd antibody companys immunotherapy mk treatment cancer ono previously licensed commercial rights antipd antibody bristolmyers squibb bms certain markets company believes patent invalid filed opposition european patent office epo seeking revocation opposition division epo scheduled hearing june hearing panel issued preliminary opinion claims patent valid hearing panel usually renders decision subject appeal close hearing patent survives proceedings similar breadth merck file actions seeking revoke patent relevant national court europe ono could file patent infringement actions company relevant national court europe around time company launches mk approved national court determines company infringed valid claim onos patent ono may entitled monetary damages including royalties future sales mk potentially could seek injunction prevent company marketing mk country addition ono bms similar patents applications company closely monitoring pending united states japan countries company confident able market mk country approved prevented ono patent pending patent environmental litigation previously disclosed merck involved pending litigation related alleged injuries caused alleged emissions site former merck subsidiary merced california also previously disclosed parties litigation reached agreement intended resolve litigation subject sufficient plaintiff participation obtained parties finalized settlement litigation dismissed prejudice january plaintiffs litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs table contents outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december purchases treasury stock include million shares purchased pursuant accelerated share repurchase agreement discussed issuances primarily reflect activity sharebased compensation plans table contents may merck entered accelerated share repurchase asr agreement goldman sachs co goldman sachs asr merck agreed purchase billion mercks common stock total initial delivery approximately million shares mercks common stock based current market price made goldman sachs merck payment billion made merck goldman sachs may upon settlement asr october merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program bringing total shares received merck program million asr entered pursuant share repurchase program announced may noncontrolling interests connection restructuring ami merck assumed billion par value preferred stock dividend rate per annum carried kbi included noncontrolling interests astrazeneca exercises option acquire mercks interest azlp see note preferred stock obligation retired sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus certain psus granted december employees participate dividends basis common shares dividends nonforfeitable holder rsus psus issued january dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior table contents weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses table contents pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries result plan design changes approved beginning january active participants mercks primary us defined benefit pension plans accruing pension benefits using new cash balance formulas based age service pay interest however transition period january december participants earn greater benefit calculated employees legacy final average pay formula new cash balance formula years service december participants earn future benefits cash balance formula addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost pension postretirement benefit plans consisted following components pension benefits postretirement benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net periodic benefit cost increase net periodic benefit cost pension postretirement benefit plans compared largely attributable change discount rate net periodic benefit cost attributable us pension plans included table million million million connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans addition settlements recorded certain domestic international pension plans table contents obligations funded status summarized information changes plan assets benefit obligation funded status amounts recorded december follows postretirement pension benefits benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial gains losses benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities fair value us pension plan assets included preceding table billion billion december respectively projected benefit obligation us pension plans billion billion respectively approximately companys pension projected benefit obligation december respectively relates international defined benefit plans individual plan significant relative total projected benefit obligation december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans pension plans projected benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligations billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets billion billion respectively accumulated benefit obligations billion billion respectively table contents plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately respectively companys pension investments year end categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts derivatives liabilities derivatives plans level investments real estate funds generally valued market appraisals underlying investments funds plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total balance january actual return plan assets relating assets still held december relating assets sold year purchases sales transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities fixed income obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities fixed income obligations company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines table contents expected contributions contributions pension plans postretirement benefit plans expected approximately million million respectively expected benefit payments expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components oci postretirement pension plans benefit plans years ended december net gain loss arising period prior service credit cost arising period net loss amortization included benefit cost prior service credit cost amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows us pension pension plans postretirement benefit plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis developing expected rate return within plan longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return range compared range us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses net increase interest income compared reflects accretion time value money discounts related certain accounts receivables including accelerated accretion related significant collections accounts receivable spain see note increase interest expense compared driven part issuances debt september may exchange losses reflect million losses due venezuelan currency devaluation february venezuelan government devalued currency bolvar fuertes vef per us dollar vef per us dollar company recognized losses due exchange approximately million resulting remeasurement local monetary assets liabilities new rate since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations net presented table reflects million net charge related settlement enhance litigation see note net reflects million charge related resolution arbitration proceeding involving companys rights market remicade simponi see note million gain disposition companys interest jjmcp joint venture see note million gain sale certain manufacturing facilities related assets see note interest paid million million million interest paid net million received company termination certain interest rate swap contracts year see note table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings tax settlements american taxpayer relief act unremitted foreign earnings tax rate changes amortization purchase accounting adjustments restructuring us health care reform legislation intangible asset impairment charges vioxx enhance litigation settlements arbitration settlement charge state taxes includes tax effect contingency reserves research credits miscellaneous items foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly singapore ireland switzerland puerto rico operates tax incentive grant earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs arbitration settlement charge items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate american taxpayer relief act signed law january extending research credit controlled foreign corporation lookthrough provisions two years retroactively january december company recorded entire benefit legislation financial statements period includes date enactment impact reflected reconciliation income taxes consisted years ended december domestic foreign table contents taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized deferred income taxes current assets assets income taxes payable deferred income taxes company net operating loss nol carryforwards several jurisdictions december approximately million deferred taxes nol carryforwards relate foreign jurisdictions none individually significant approximately million valuation allowances established foreign nol carryforwards foreign deferred tax assets addition company approximately million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively tax benefits relating stock option exercises reflected paidin capital million million amounts material table contents reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs cra discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted benefit million million million amounts reflect beneficial impacts various tax settlements including discussed liabilities accrued interest penalties million billion december respectively internal revenue service irs finalized examination scheringploughs tax years companys unrecognized tax benefits years examination exceeded adjustments related examination period therefore company recorded net million tax provision benefit irs finalized examination scheringploughs tax years audit cycle company reached agreement irs adjustment income related intercompany pricing matters income adjustment mostly reduced nols tax credit carryforwards companys reserves uncertain tax positions adequate cover adjustments related examination period additionally previously disclosed company seeking resolution one issue raised examination irs administrative appeals process company recorded outofperiod net tax benefit million related issue settled fourth quarter final resolution relating interest owed reached first quarter companys unrecognized tax benefits related issue exceeded settlement amount management concluded exclusion benefit material current prior year financial statements previously disclosed canada revenue agency cra proposed adjustments relating intercompany pricing matters july cra issued assessments miscellaneous audit issues tax years merck cra reached settlement years calls merck pay additional canadian tax approximately million companys unrecognized tax benefits related matters exceeded settlement amount therefore company recorded net million tax provision benefit portion taxes paid expected creditable us tax purposes company previously established reserves matters resolution matters material effect companys results operations financial position liquidity irs concluded examination mercks federal income tax returns result company required make net payments approximately million companys unrecognized tax benefits years examination exceeded adjustments related examination period therefore company recorded net million tax provision benefit net benefit reflects decrease unrecognized tax benefits years examination partially offset increases unrecognized tax benefits years subsequent table contents examination period result settlement company disagrees irs treatment one issue raised examination appealing matter irs administrative process addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability addition company subsidiaries operating puerto rico singapore tax incentive grants began expire earnings per share prior company calculated earnings per share pursuant twoclass method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends rsus certain psus granted december generally three year vesting period certain management level employees met definition participating securities rsus psus issued january meet definition participating securities therefore beginning company longer applies twoclass method calculations earnings per share follows years ended december basic earnings per common share net income attributable merck co inc less income allocated participating securities net income allocated common shareholders average common shares outstanding earnings per common share assuming dilution net income attributable merck co inc less income allocated participating securities net income allocated common shareholders average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss first quarter company adopted guidance issued fasb requires additional disclosure related impact reclassification adjustments aoci net income changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains sales availableforsale investments reclassified aoci income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december included cumulative translation adjustment pretax gains approximately million relating translation impacts intangible assets recorded conjunction merger table contents segment reporting companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances includes revenue equity income companys relationship azlp animal health consumer care alliances segments material separate reporting included table pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets well club stores specialty channels accounting policies segments described described note table contents sales companys products follows years ended december primary care womens health cardiovascular zetia vytorin diabetes obesity januvia janumet respiratory nasonex singulair dulera asmanex womens health endocrine nuvaring fosamax follistim aq implanon cerazette arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress cancidas pegintron invanz victrelis noxafil oncology temodar emend cosopttrusopt bridion integrilin diversified brands cozaarhyzaar primaxin zocor propecia clarinex remeron claritin rx proscar maxalt vaccines gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sales segment sales total segment sales amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health consumer care alliances alliances segment includes revenue companys relationship azlp revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results october company divested substantial portion thirdparty manufacturing sales see note addition revenues reflect million revenue outlicense pipeline compound table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan asia pacific latin america reconciliation total segment profits consolidated income taxes follows years ended december segment profits pharmaceutical segment segments total segment profits profits losses unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs net charge related settlement enhance litigation arbitration settlement charge unallocated net segment profits comprised segment sales less standard costs certain operating expenses directly incurred segments internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits losses primarily comprised miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales divested products businesses supply sales unallocated net includes expenses corporate manufacturing cost centers product intangible asset impairment charges gain losses sales businesses miscellaneous income expense items table contents equity income affiliates depreciation amortization included segment profits follows pharmaceutical total year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization property plant equipment net geographic area located follows years ended december united states europe middle east africa asia pacific latin america japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income comprehensive income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso companys management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report item responsibility express opinions financial statements companys internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders amounts include net charge related settlement certain shareholder litigation see note amounts include net benefits relating settlements certain federal income tax issues see note amounts reflect acquisitionrelated costs see note impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training includes financial stewardship training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december table contents inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier peter n kellogg chairman president executive vice president chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomaboutcodeofconductpdf every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior printed copy sent without charge shareholder requests writing chief ethics compliance officer merck co inc one merck drive whitehouse station nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans msd employee savings security plan scheringplough employees savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans shares restricted stock units performance share units excluding accrued dividends merck co inc schering plough stock incentive plan also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred msd directors deferral program item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion audit committee beginning caption pre approval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item